onsite programme

Transcription

onsite programme

ONSITE PROGRAMME
13TH INTERNATIONAL CONFERENCE OF THE
INTERNATIONAL MESOTHELIOMA INTEREST GROUP
Follow us on Twitter @iMig_meso
for updates during the Conference!
iMig 2016 wishes to warmly thank the
following organizations for their generous
support of the Conference:
GOLD SPONSORS
SILVER SPONSORS
BRONZE SPONSORS
SUPPORTERS
EDUCATIONAL
GRANT PROVIDER
This meeting is supported by an
unrestricted educational grant from
Roche Products Ltd. who have had no input into
the meeting agenda or content.
This meeting is supported by an
unrestricted educational grant from Concordia
Laboratories Inc. who have had no input into
the meeting agenda or content.
GENERAL SUPPORT
iMig 2016 would like to thank the following organizations for their support
of the Conference:
Cancer Research UK
Leicester Centre
MRC Toxicology Unit
TABLE OF CONTENTS
SCIENTIFIC INFORMATION
CONFERENCE INFORMATION
Welcome Message
2
International Mesothelioma
Interest Group
3
Committees
3
Scientific Programme
Programme at a Glance
4
Monday, May 2, 2016
6
Tuesday, May 3, 2016
18
Wednesday, May 4, 2016
30
Information for Invited Speakers
and Abstract Presenters
32
Conference Information
37
37
Floor Plans
General Information from A to Z
38
Awards
44
iMig Wagner Medal
44
iMig Medal
44
iMig Award
44
Best Investigator Award
45
Young Investigator Awards
45
Developing Nations Travel Grants
45
Special Workshop:
Mesothelioma Nurse Meeting
46
Industry-Supported Symposia
49
Exhibition Information
Location, Hours and Highlights
50
Exhibitor Listing
54
Exhibition Floor Plan
55
Exhibitor Biographies
56
GENERAL SUPPORT
iMig 2016 is organized
under the auspices of the
iMig2016.ORG
iMig 2016 is
endorsed by the
13TH INTERNATIONAL CONFERENCE OF THE I NTERNATIONAL MESOTHELIOMA INTEREST GROUP
1
WELCOME MESSAGE
It is a great pleasure and an honour to
extend you a warm invitation to attend the
13th International Conference of the
International Mesothelioma Interest
Group (iMig 2016), to be held May 1–4,
2016 at the International Conference
Centre in Birmingham, UK.
Building on the success of preceding
meetings in Boston in 2012 and Cape
Town in 2014, the Conference will feature
a highly interactive, stimulating and
multidisciplinary Programme including
workshops, plenary sessions as well as
oral abstract and poster sessions. Under
the theme of ‘Towards Personalized Care’
the meeting will address the entire patient
pathway and look beyond the scientific
topics alone.
The Conference will provide the ideal
forum to stimulate ideas and establish
collaborations as well as to initiate
intense discussions. Extended networking
opportunities will foster communications
between delegates.
It is an exciting time for mesothelioma research and we hope to see you in Birmingham
in 2016 for the iMig 2016 Conference.
With best wishes,

David Waller
Glenfield Hospital
2
Dean A. Fennell
University of Leicester
iMig2016.ORG
INTERNATIONAL MESOTHELIOMA INTEREST GROUP
WWW.IMIG.ORG
The International Mesothelioma Interest
Group (iMig) is an independent international group of scientists and clinicians
working to understand, cure and prevent
Mesothelioma. We invite you to become
a member of iMig to strengthen our
international voice and to improve the
scientific exchange and knowledge about
this malignancy.
WHY JOIN IMIG?
Membership is about communication
and participation. Members will have
access to all features of the iMig website
(iMig.org) and opportunities to contribute
content there. Via email, members will
receive notices of updates to the website
such as those involving upcoming meetings, funding or career opportunities,
new presentations and research breakthroughs. Although no membership dues
are requested at this time, members are
asked to participate in iMig by contributing to the website and/or participating in
the biannual international meetings.
Finally, members help iMig by being
part of our international community and
showing their interest in understanding
and ultimately preventing and defeating
Mesothelioma.
iMig2016.ORG
iMig OFFICERS 2014 – 2016
President: Dean Fennell, PhD, MRCP,
Leicester, United Kingdom
Secretary: Jeremy Steele, MD, MRCP,
London, United Kingdom
Treasurer: Paul Baas, MD, PhD,
Amsterdam, The Netherlands
iMig BOARD MEMBERS 2014 – 2016
Steve Albelda, MD, Philadelphia, USA
Samuel Armato, PhD, Chicago, USA
Paul Baas, MD, PhD, Amsterdam, The Netherlands
Courtney Broaddus, MD, San Francisco, USA
Dean Fennell, MD, PhD, Leicester, United Kingdom
Rabab Gaafar, MD, Cairo, Egypt
Marie-Claude Jaurand, PhD, Paris, France
Hedy Lee Kindler, MD, Chicago, USA
Steven Mutsaers, MD, PhD, Perth, Australia
Luciano Mutti, MD, PhD, Vercelli, Italy
Takashi Nakano, MD, PhD, Hyogo, Japan
Bruce Robinson, MD, Perth, Australia
Arnaud Scherpereel, MD, PhD, Lille, France
Jeremy Steele, MD, London, United Kingdom
Daniel Sterman, MD, Philadelphia, USA
Jim teWaterNaude, MBChb, Cape Town, South Africa
Walter Weder, MD, Zurich, Switzerland
LOCAL ORGANIZING COMMITTEE
Co-Chairs:
David Waller, MD, Leicester, United Kingdom
Dean Fennell, PhD, MRCP, Leicester, United Kingdom
Samuel Armato, PhD, Chicago, USA
Sara Busacca, Leicester, United Kingdom
Liz Darlison, Leicester, United Kingdom
Laurie Kazan-Allen, London, United Kingdom
Marion MacFarlane, PhD, Leicester, United Kingdom
Luciano Mutti, MD, PhD, Vercelli, Italy
Mick Peake, MD, Leicester, United Kingdom
Sanjay Popat, BSc, PhD, FRCP, London, United Kingdom
Annabel Sharkey, Leicester, United Kingdom
Jeremy Steele, MD, London, United Kingdom
Lynne Squibb, Southampton, United Kingdom
Ian Woolhouse, Birmingham, United Kingdom
3
PROGRAMME AT A GLANCE
MONDAY | MAY 2
08:00
08:30
09:00
09:30
Plenary Session I:
Origins of Mesothelioma
[08:25 – 10:25]
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
Networking Break and Poster Viewing
Plenary Session II:
Predicting the Outcome
[11:15 – 12: 45]
Networking Break
and Poster Viewing
[12: 45 – 14:15]
Lunchtime Session
[13:15 – 14:15]
Parallel Mini Symposia
1–4
[14:15 – 15: 45]
17:00
5–8
17:30
[16: 30 – 18: 00]
18:00
18:30
19:00
Poster Mixer with Poster Discussions
[18: 00 – 19: 30]
19:30
20:00
20:30
21:00
4
iMig2016.ORG
TUESDAY | MAY 3
WEDNESDAY | MAY 4
Industry-Supported Symposium
Industry-Supported Symposium
08:00
[08: 00 – 08: 45]
[08: 00 – 08: 45]
08:30
Plenary Session III:
The Knife or the Needle?
Plenary Session V:
What is in the Locker Now?
[09: 00 – 10: 30]
[09: 00 – 10: 30]
Plenary Session IV:
From Genetics to Therapy
Plenary Session VI:
The “Immune War” on Mesothelioma
[11:15 – 12: 45]
[11:15 – 12: 45]
09:00
09:30
10:00
10:30
Networking Break
and Poster Viewing
[12: 45 – 14:15]
9–12
11:30
12:00
12:30
Presidential Closing and Invitation to iMig 2018
Industry-Supported
Symposium
[13:15 – 14:15]
11:00
13:00
13:30
Young Investigator’s Session
[13: 30 – 15: 30]
14:00
14:30
15:00
[14:15 – 15: 45]
15:30
16:00
16:30
13–16
17:00
[16: 30 – 18: 00]
17:30
18:00
18:30
Poster Mixer with Poster Discussions
[18: 00 – 19: 30]
19:00
19:30
20:00
20:30
21:00
*subject to change
iMig2016.ORG
5
MONDAY, MAY 2, 2016
INITIATION AND DETECTION OF MESOTHELIOMA
08:25 – 10:25
PL01: Plenary Session I:
Origins of Mesothelioma
Chairs: Jim teWaterNaude, South Africa &
Dean Fennell, United Kingdom & Daniel
Sterman, USA
Hall 1
08:25
PL01.01: Welcome Address
Dean Fennell, University of Leicester,
United Kingdom
08:30
PL01.02: The Global Meso Epidemic
Julian Peto, London School of
Hygiene and Tropical Medicine,
United Kingdom
08:50
PL01.03: Chrysotile and Cancer
Julian Peto, London School of
Hygiene and Tropical Medicine,
United Kingdom & David Egilman,
Brown University, USA
09:10
PL01.07: The Genomic Landscape of
Mesothelioma
Patrick Tarpey, Wellcome Trust Sanger
Institute, United Kingdom
10:00
PL01.08: How the Genome Affects
Outcome
Raphael Bueno, Brigham and Women’s
Hospital and Harvard Medical School,
USA
10:15
PL01.09: Constitutive YAP Activation
Induces Malignant Phenotypes of
Immortalized Mesothelial Cells
Yoshitaka Sekido, Aichi Cancer Center
Research Institute, Japan
10:30 – 11:15
Networking Break
and Poster Viewing
Hall 3
PL01.04: Pleural Mesothelioma
and Asbestos Exposure: A CaseControl Study with Quantitative Risk
Assessment
11:15 – 12:45
Daniela Ferrante, University of Eastern
Piedmont, Italy
PL02: Plenary Session II:
Predicting the Outcome
09:20
PL01.05: Mechanisms of Asbestos
Carcinogenesis and HMGB1
Haining Yang, University of Hawaii
Cancer Center, USA
Chairs: Steve Mutsaers, Australia & John
Edwards, United Kingdom & Sam
Armato, USA
09:35
PL01.06: Long-Fibre Carbon
Nanotubes Induce Pleural
Mesothelioma via Silencing and/
or Loss of Key Tumour Suppressor
Genes
6
09:45
Hall 1
11:15
PL02.01: “The Bad Macrophage
Story”
Lisa Coussens, Oregon Health & Science
University, USA
Tatyana Chernova, MRC Toxicology Unit,
United Kingdom
iMig2016.ORG
MONDAY, MAY 2
PL02.02: Clinico-Pathological Staging
- the New IASLC System
Valerie Rusch, Memorial Sloan Kettering
Cancer Center, USA
11:55
PL02.03: Impact of Tumor Thickness
on Survival after Accelerated
Hemithoracic Radiation Followed by
Extrapleural Pneumonectomy
Marc De Perrot, Toronto General
Hospital and Princess Margaret Cancer
Center, Canada
12:05
PL02.04: “Bio Staging” - the Future
Kenneth O’Byrne, Queensland University
of Technology, Australia
12:25
PL02.05: Mutation Profiles of
Malignant Pleural Mesotheliomas
According to Molecular Classification
Lisa Quetel, INSERM U.1162, France
12:35
PL02.06: Final Q & A
14:15 – 15:45
PARALLEL MINI SYMPOSIA 1 - 4
MS01: Mini Symposium 1:
MARF International Meso UK
Mini Symposium
Chairs: Mary Hesdorffer, USA & Liz Darlison,
United Kingdom & Judy Rafferty,
Australia
Hall 10a
14:15
MS01.01: Welcome
Liz Darlison, Mesothelioma UK, United
Kingdom
14:20
MS01.02: Managing Toxicities &
Supporting Patients through Radical
Radiotherapy
Anastasia Bykova, University Health
Network, Canada
14:40
MS01.03: Surgical Panel
Joseph Friedberg, University of Maryland
School of Medicine, USA & Walter Weder,
University Hospital Zurich, Switzerland
& John Edwards, Northern General
Hospital, United Kingdom & Melissa
Culligan, University of Maryland, USA
15:10
MS01.04: Programme for Nurses to
Improve Communication Skills in the
Care of People With Mesothelioma in
Japan
Yasuko Nagamatsu, St. Luke’s
International University, Japan
15:20
MS01.05: Mesothelioma Patients’
and Carers’ Concerns about Their
Diagnosis, Treatment, and Care
Kate Hill, Leeds Institute of Health
Sciences, United Kingdom
12:45 – 14:15
Networking Break
and Poster Viewing
Hall 3
13:00 – 14:00
SS02: Lunchtime Session:
How Much Cancer Does
Chrysotile Cause?
Chairs: Jim teWaterNaude, South Africa &
Laurie Kazan-Allen, United Kingdom
Hall 1
13:15
SS02.01: How Much Cancer Does
Chrysotile Cause?
Julian Peto, London School of Hygiene
and Tropical Medicine, United Kingdom,
David Egilman, Brown University, USA
iMig2016.ORG
MONDAY, MAY 2
11:35
7
MONDAY, MAY 2
MS01.06: Asbestos-Related Disease
Support Groups: A Survey of Their
Organisational Structures and
Activities
15:00
MS02.05: Tissue Transglutaminase
(TG2): A Potential Novel Target
for Human Malignant Pleural
Mesothelioma Treatment
Helen Clayson, Glasgow Caledonian
University, United Kingdom
Giulia Pinton, University of Piemonte
Orientale, Italy
15:40
MS01.07: Close
15:10
Kingdom
MS02.06: Autophagy Inhibition
Sensitizes Primary Malignant
Mesothelioma to a Dual PI3K/mTOR
Inhibitor
Sara Galavotti, MRC Toxicology Unit,
United Kingdom
Cell Death Mechanisms
15:20
MS02.07: Autophagy Correlates with
Patient Outcome in Mesothelioma
Chairs: Courtney Broaddus, USA & Marion
MacFarlane, United Kingdom
Carlo Follo, University of California San
Francisco, USA
15:30
MS02.08: What Have We Learned?
Marion Macfarlane, MRC Toxicology
Unit / Cancer Research UK Centre,
United Kingdom
MONDAY, MAY 2
15:30
8
14:15 – 15:45
Hall 10b
14:15
MS02.01: Setting the Stage for Cell
Death
Courtney Broaddus, University of
California San Francisco, USA
14:30
MS02.02: Signalling Pathways
Involved in Upregulation of MCL1
in MM; Metabolic Reprogramming
Provides a Novel Approach to
Sensitise MM
Xiao-Ming Sun, MRC Toxicology Unit,
United Kingdom
14:40
MS02.03: Monoamine Oxydase A
as a Potential New Target to Treat
Malignant Pleural Mesothelioma
Christophe Blanquart, University of
Nantes, France
14:50
MS02.04: EGFR Tyrosine Kinase
Inhibitors Overcome Resistance to
Chemotherapy in Malignant Pleural
Mesothelioma
Ludovic Dhont, Interdisciplinary Cluster
for Applied Genoproteomics (GIGA) of
University of Liège, Belgium
14:15 – 15:45
Imaging and Endpoint Evaluation
Chairs: Samuel Armato, USA & Anna Nowak,
Australia
Hall 6
14:15
MS03.01: Indocyanine Green and
Intraoperative Imaging Detects
Residual Disease Following
Resection of Malignant Pleural
Mesothelioma
Jane Keating, University of Pennsylvania,
USA
iMig2016.ORG
MONDAY, MAY 2
MS03.02: The Value of Delayed
Phase Enhancement for Magnetic
Resonance Imaging of Malignant
Pleural Mesothelioma
Sharyn Katz, University of Pennsylvania
Perelman School of Medicine, USA
14:35
MS03.03: Optimisation of the Methods
for Early Contrast Enhancement
(ECE)-Magnetic Resonance Imaging
in Patients with Mesothelioma
Selina Tsim, Queen Elizabeth University
Hospital, United Kingdom
14:45
MS03.04: Histogram Analysis of DWMRI Data during Early Chemotherapy
Response Predicts Outcome of
Inoperable MPM Patients
Johan Coolen, University Hospitals of
Leuven, Belgium
14:55
MS03.05: Correlation of CT Scan
Based Tumor Volume Measurement
to Actual Resected Tumor Weight: A
New T-Factor?
Isabelle Opitz, University Hospital
Zürich, Switzerland
15:05
MS03.06: Dynamic ContrastEnhanced CT for the Assessment of
Tumor Response in Malignant Pleural
Mesothelioma: A Pilot Study
Eyjolfur Gudmundsson, University of
Chicago, USA
15:15
MS03.07: Modified RECIST for
Mesothelioma: Lessons Learned and
Gaps in Application
Anna Nowak, University of Western
Australia, Australia
15:25
MS03.08: Toward Modified RECIST 1.1
for Mesothelioma: Closing the Gaps
and Meeting Present-Day Needs
Sam Armato, University of Chicago, USA
iMig2016.ORG
15:35
MS03.09: Final Q & A
14:15 – 15:45
MS 04: Mini Symposium 4:
Cell and Vaccine Based Therapy
Chairs: Bruce Robinson, Australia & Steve
Albelda, USA
Hall 9
14:15
MS04.01: Introduction
MONDAY, MAY 2
14:25
14:25
MS04.02: Experimental Models of
Human Malignant Mesothelioma in
NOD SCID Mice and Nude Rats for
Evaluation of in Vivo Virotherapy
Joëlle Nader, UMR 892 INSERM / 6299
CNRS, France
14:35
MS04.03: Tumour Suppressor
microRNAs Regulate PD-L1
Expression in Malignant Pleural
Mesothelioma
Marissa Williams, Asbestos Diseases
Research Institute, Australia
14:45
MS04.04: PD-1+ T Cells in
Mesothelioma Effusions Induce
Tumor PD-L1 Expression Making
Them Susceptible to Avelumab
Mediated ADCC
Raffit Hassan, National Cancer Institute,
USA
14:55
MS04.05: Harnessing the Immune
System-Adjuvant Immunotherapy for
Mesothelioma
Jarrod Predina, University of
Pennsylvania School of Medicine, USA
9
MONDAY, MAY 2
MS04.06: Intrapleural Modified
Vaccine Strain Measles Virus Therapy
for Patients with Malignant Pleural
Mesothelioma - A Phase I Trial
Tobias Peikert, Mayo Clinic, USA
15:15
MS04.07: Nivolumab in Malignant
Pleural Mesothelioma (NivoMes): An
Interim Analysis
Josine Quispel-Janssen, Netherlands
Cancer Institute, Netherlands
MONDAY, MAY 2
15:05
16:40
MS05.02: Haptoglobin Phenotype Is
a Risk Factor for Malignant Pleural
Mesothelioma
Kevin Lamote, Ghent University Hospital,
Belgium
16:50
MS05.03: HMGB1 and Its Isoform Are
Sensitive and Specific Biomarkers
to Detect Asbestos Exposure and to
Identify Mesothelioma Patients
Haining Yang, University of Hawaii
Cancer Center, USA
17:00
MS05.04: Expression of microRNAs
in MPM as Tool to Identify Novel
Therapeutic Targets and Diagnostic/
Prognostic Biomarkers
15:25
MS04.08: Immune Responses
following Intrapleural Administration
of Oncolytic HSV1716 in Patients with
Kevin Blyth, Queen Elizabeth University
Chiara De Santi, University of Pisa, Italy
17:10
MS05.05: The Role of
Multidisciplinary Diagnostic/
Therapeutic Pathway in the CaseManagement of Suspected Pleural
Mesothelioma
Cristian Rapicetta, Arcispedale Santa
Maria Nuova-IRCCS, Italy
17:20
MS05.06: Launching the North
West Regional Mesothelioma MDT;
Defining the Patient Pathway
Lorraine Creech, University Hospital of
South Manchester, United Kingdom
17:30
15:35
15:45 – 16:30
Networking Break
and Poster Viewing
Hall 3
16:30 – 18:00
PARALLEL MINI SYMPOSIA 5 - 8
Optimum Diagnostic Pathway for
Suspected Mesothelioma
Chairs: Takashi Nakano, Japan & Robert Rintoul,
United Kingdom
Hall 6
10
16:30
MS05.01: MesobanK - Today’s
Biospecimens for Tomorrow’s
Medicine
Robert Rintoul, Papworth Hospital NHS
Foundation Trust, United Kingdom
16:30 – 18:00
Asbestos Control
Chairs: Jim teWaterNaude, South Africa & Laurie
Kazan-Allen, United Kingdom
Hall 9
iMig2016.ORG
MONDAY, MAY 2
MS06.01: Turkey National
Mesothelioma Surveillance Program
and Asbestos Control
Muzaffer Metintas, Eskisehir Osmangazi
University, Turkey
16:40
MS06.02: Mesothelioma Mortality At
10-year Follow-up In The Atom 002
Screening Study
Ornella Belvedere, York Hospital, United
Kingdom
16:50
MS06.03: Factors Influencing the
Asbestos Bodies among Pleural
Mesotheliomas and Lung Cancers
Examined for Retained Asbestos
Fibres
Enzo Merler, Venetian Mesothelioma
Registry, Italy
17:00
MS06.04: An Ecological Analysis of
Cohorts with Environmental and
Occupational Mineral Fiber Exposure
Selma Metintas, Eskisehir Osmangazi
University, Turkey
17:10
MS06.05: The Impact of Geographic
and Socioeconomic Factors on
Prognosis and Treatment Provision in
16:30 – 18:00
BAP1 and Genetics
Chairs: Michele Carbone, USA & Marc Ladanyi,
USA
Hall 10a
16:30
MS07.01: Association of BAP1 Gene
Expression with Protein Localization
and Survival in Epithelioid MPM
Assunta De Rienzo, Brigham and
Women’s Hospital and Harvard Medical
School, USA
16:40
MS07.02: Somatic BAP1 and NF2
Mutations in Pleural Malignant
Mesothelioma and Their Correlation
with Clinical Phenotypes
Spyridon Gennatas, Imperial College
16:50
MS07.03: Families with Multiple
Cases of Pleural Malignant
Mesothelioma without Inheritance of
a BAP1 Predisposing Mutation
Valeria Ascoli, Sapienza University, Italy
17:00
MS07.04: BAP1 and Mesothelioma
Michele Carbone, University of Hawaii
Cancer Center, USA
17:10
MS07.05: BAP-1 Cancer Syndrome
Associated Malignancies Were Not
Detected among 558 Danish Patients
with Malignant Mesothelioma
Anthony Linton, Asbestos Diseases
17:20
MS06.06: Risk of Second
Primary Cancers after Malignant
Mesothelioma and Vice Versa
Tianhui Chen, Zhejiang Academy of
Medical Sciences, China
Vasiliki Panou, Aalborg University
Hospital & Aalborg University, Denmark
17:30
MS06.07: Mesothelioma Incidence in
Sweden - Why Does It Not Go Down?
17:20
Gunnar Hillerdal, Gävle Hospital,
Sweden
17:40
iMig2016.ORG
MONDAY, MAY 2
16:30
11
MONDAY, MAY 2
16:30 – 18:00
17:30
MS08.07: The Crucial
Clinicopathological Approach
in Superficial Mesothelial
Proliferations; MESOPATH
Experience
Francoise Galateau Salle, Cancer Center
Leon Berard, France
17:40
MS08.08: Multi-Omics Integration
for Malignant Pleural Mesothelioma
Subtypes Characterization
Yuna Blum, Ligue Nationale Contre Le
Cancer, France
17:50
Pathology
MONDAY, MAY 2
Chairs: Marie-Claude Jaurand, France & Doris
Rassl, United Kingdom
12
Hall 10b
16:30
MS08.01: Immunohistochemical
Detection of MTAP or BAP1 Protein
Loss for Mesothelioma Diagnosis:
Comparison with p16 FISH
Kazuki Nabeshima, Fukuoka University
School of Medicine, Japan
16:40
MS08.02: Utility of BAP1
Immunohistochemistry and FISH
in the Differential Diagnosis of
Malignant Mesothelioma
Kenzo Hiroshima, Tokyo Women’s
Medical University, Japan
16:50
MS08.03: Histological Evaluation of
Mesotheliomas
Gregor Vlacic, University Clinic Golnik,
Slovenia
17:00
MS08.04: A Gene Panel to
Differentiate Malignant Pleural
Mesotheliomas from Benign Pleural
Lesions
Rossella Bruno, University of Pisa, Italy
17:10
MS08.05: Necrosis and Solid Growth
Pattern Augment Nuclear Grading
in Predicting Survival in Epithelioid
Aliya Husain, University of Chicago, USA
17:20
MS08.06: Peritoneal Mesothelioma:
Evaluation on Pathology Reporting
Valeria Ascoli, Sapienza University, Italy
18:00 – 19:30
PP01
Poster Mixer and Poster
Discussion Session 1
Moderators: Michael Peake, United Kingdom &
Sam Armato, USA & Kevin Blyth, United
Kingdom & Marie Claude Jaurand,
France & Faheez Mohamed, United
Kingdom & Courtney Broaddus, USA &
Marion MacFarlane, United Kingdom
Hall 3
PP01.01: Systemic Inflammation Consistently
Predicts Adverse Outcome Based on
Multiple Biomarkers in Patients with
Mesothelioma
Michael McGettrick, Queen Elizabeth
University Hospital, United Kingdom
PP01.02: An Update on DIAPHRAGM: A
Prospective, Multi-Centre Study of
Fibulin-3 and SOMAscan as Biomarkers
in Mesothelioma
Selina Tsim, Queen Elizabeth University
iMig2016.ORG
MONDAY, MAY 2
Taiichiro Otsuki, Hyogo College of
Medicine, Japan
PP01.04: PI3-Kinase Pathway and MET Inhibition
is Efficacious in Malignant Pleural
Mesothelioma
PP01.10: Prognostic Significance of Mitotic Arrest
Deficient 2-Like Protein 1 in Malignant
Mesothelioma
Aaron Mansfield, Mayo Clinic, USA
PP01.11: Brain-Derived Neurotrophic Factor
(BDNF) and Fibulin-3 as Biomarkers
for Diagnosis of Malignant Pleural
Mesothelioma (MPM)
Rajani Kanteti, University of Chicago,
USA
Sarah Benziane, Hospital of the
University (CHU) of Lille, France
PP01.12: Target Trial
PP01.05: Early Diagnosis by Cytology Improves
Survival
Anders Hjerpe, Karolinska University
Hospital, Sweden
PP01.06: Low Merlin Expression and High Survivin
Staining Index are Indicators for Poor
Prognosis of Malignant Mesothelioma
Patients
Mayura Meerang, University Hospital
PP01.07: MicroRNAs in Blood as Biomarker of
Pleural Malignant Mesothelioma
Dario Consonni, Fondazione IRCCS Ca’
Granda - Ospedale Maggiore Policlinico,
Italy
Duneesha De Fonseka, North Bristol
NHS Trust, United Kingdom
PP01.13: Ex Vivo Effects of Pemetrexed and
Carboplatin on Malignant Mesothelioma
Cells
Carl-Olof Hillerdal, Karolinska Institutet,
Sweden
PP01.14: Diagnosing Mesothelioma via Chest Wall
Motion Analysis Technology
Ghazi Elshafie, Heartlands Hospital,
United Kingdom
PP01.15: Circulating Level of the Complement
Component 4d (C4d) Correlates with
Chemotherapeutic Response and
Survival in MPM Patients
PP01.08: Septin-7, Lipoma Preferred Partner and
Transaldolase Discriminate Neoplastic
From Preneoplastic Mesothelial Cells
PP01.16: VOC Analysis in Headspace Air of
Mesothelioma and Lung Cancer Cell
Lines: A Comparative Literature Study
Daniel Pouliquen, UMR 892 INSERM /
6299 CNRS, France
PP01.09: Col3A1, a New Potential
Immunohistological Marker for
the Diagnosis of Malignant Pleural
Mesothelioma
Christophe Blanquart, INSERM UMR 892
/ CNRS 6299, France
Thomas Klikovits, Medical University of
Vienna, Austria
Sabrina Lagniau, Ghent University,
Belgium
PP01.17: Prognostic Biomarkers in a Large Cohort
of Patients with Malignant Pleural
Mesothelioma - a Retrospective TwoCenter Study
iMig2016.ORG
MONDAY, MAY 2
PP01.03: Examination of the Serum Soluble
Mesothelin-Related Peptide (SMRP)
Level in Patients with Malignant Pleural
Mesothelioma
Thomas Klikovits, Medical University of
Vienna, Austria
13
MONDAY, MAY 2
PP01.18: Changes in Monocyte Count and
Lymphocyte-To-Monocyte Ratio during
Induction Chemotherapy Correlate with
Clinical Outcome
MONDAY, MAY 2
Jens Sørensen, Finsen Centre/National
University Hospital, Denmark
PP01.28: Phase I Trial of Lentiviral CART-Meso
Cells in Progressive Malignant Pleural
Mesothelioma (MPM)
Luca Ampollini, University Hospital of
Parma, Italy
Steven Albelda, University of
Pennsylvania, USA
PP01.21: Serum Biomarkers in Mesothelioma 1-3
Years before Diagnosis: A Pilot Study
PP01.29: Does Malignant Pleural Mesothelioma
with Metastases at First Presentation
Really Benefit from Chemotherapy?
Oluf Røe, Norwegian University of
Science and Technology, Norway
PP01.22: Role of EPHA2 in Malignant
Mesothelioma
Yi-Hung Carol Tan, University of Chicago,
USA
Bruce Robinson, University of Western
PP01.24: Prognostic microRNAs in Tissues from
Malignant Pleural Mesothelioma Patients
Receiving Multimodality Therapy
Michaela Kirschner, University Hospital
Zurich, Switzerland
Guntulu Ak, Eskisehir Osmangazi
University, Turkey
Nicholas De Klerk, University of Western
PP01.31: Preliminary Report of an Observational
Clinical Registry on Malignant Pleural
Mesothelioma (MPM) in Italy (REGCLIN)
Federica Grosso, SS. Antonio e Biagio e
C. Arrigo, Hospital, Italy
PP01.32: Slowly Progressive Malignant Pleural
Mesothelioma in Aged Patients
PP01.25: Chemotherapy and Chemotherapy
Plus Talc Pleurodesis In Treatment of
Malignant Pleural Mesothelioma: A
Retrospective Analysis
Hala Aziz Shokralla, National Cancer
Institute, Egypt
PP01.30: Mesothelioma Mortality in Australian
and Italian-Born Workers Exposed to
Blue Asbestos at Wittenoom, Western
Australia
PP01.23: ENOX2-Based Early Detection of
Mizue Hasegawa, Tokyo Women’s
Medical University, Japan
PP01.33: A Cohort of Malignant Pleural
Mesothelioma Treated and Followed
in the Last Ten Years at Instituto
OncolóGico Henry Moore
14
Hasan Batirel, Marmara University,
Turkey
PP01.27: Fourth Line Chemotherapy with
Docetaxel for Malignant Pleural
Mesothelioma (MPM)
Michaela Kirschner, University Hospital
Zurich, Switzerland
PP01.20: Tumor-Infiltrating Lymphocytes and
BAP-1, VEGFR-2, IGF-1R Expression in
Mir Hoda, Medical University of Vienna,
Austria
PP01.19: Combining Cell-Free microRNAs and
SMRP: A Multi-Biomarker Signature with
Improved Diagnostic Accuracy
PP01.26: Initial Results of the Multicentric
Turkish Malignant Pleural Mesothelioma
Database*
Mariana Abal, Instituto Oncologico
Henry Moore, Argentina
iMig2016.ORG
MONDAY, MAY 2
Nobukazu Fujimoto, Okayama Rosai
Hospital, Japan
PP01.35: Malignant Pleural Mesothelioma in
Patients Older than 45 Years
Fatma Aou El-Kasem, National Cancer
Institute, Egypt
PP01.36: A Mesothelioma Cluster Amongst
Experimental Physicists
Steven Kazan, Kazan McClain Satterley
& Greenwood, USA
PP01.37: Survival in Good Performance Malignant
Pleural Mesothelioma Patients;
Prognostic Factors and Predictors of
Response
Institute, Egypt
PP01.38: Non-Epithelial Pleural Mesothelioma;
Criteria, Prognostic Factors and
Predictors of Response
Institute, Egypt
PP01.39: Does Pretreatment Body Weight Have
Any Significant Impact on Survival in
Pleural Mesothelioma in Young Age
Group?
Institute, Egypt
PP01.40: Malignant Pleural Mesotheliom: A
Single-Center Experience in Croatia
Marko Jakopovic, University Hospital
Center Zagreb, Croatia
PP01.41: Mesothelioma Incidence in Lombardy,
Italy: Time Patterns and Future
Projections
PP01.42: Clinico Pathological Characteristics
of Young Egyptian Malignant Pleural
Mesothelioma Patients
Institute, Egypt
PP01.43: Increasing Age at Diagnosis in
the Australian Malignant Pleural
Mesothelioma Population: What Are the
Potential Implications?
Matthew Soeberg, Asbestos Diseases
PP01.44: Study on the Evolution over Time of the
Risk of Mesothelioma and Lung Cancer
among Former Asbestos-Exposed
Workers
Corrado Magnani, University Eastern
Medicine, Italy
PP01.46: Mortality/Hospitalization From
Pleural Mesothelioma Associated With
Environmental Exposure to FluoroEdenite in Biancavilla
MONDAY, MAY 2
PP01.34: Brain Metastases in Malignant Pleural
Mesothelioma
Susanna Conti, Istituto Superiore di
Sanità, Italy
PP01.47: Survival and Expected Years of Life Lost
of Malignant Mesothelioma: Analysis of
105 Cases in Taiwan, 1977-2015
Lukas Lee, National Health Research
Institutes, Taiwan
PP01.50: Investigating Palygorskite’s Role in
the Development of Mesothelioma in
Southern Nevada
Cancer Center, USA
PP01.51: Mesothelioma Mortality in Poland
Between 1999 and 2013
Anna Minkiewicz, Medical University of
Warsaw, Poland
Italy
iMig2016.ORG
15
MONDAY, MAY 2
PP01.62: Malignant Pleural Mesothelioma
in Austria: Data from the Austrian
Mesothelioma Interest Group Database
MONDAY, MAY 2
PP01.52: Relationship between Histological Type
and Pleural Effusion in Malignant Pleural
Mesothelioma
Koji Mikami, Hyogo College of Medicine,
Japan
PP01.53: Pattern Of Malignant Pleural
Mesothelioma in Egyptian Patients
PP01.63: Histopathological Reporting of
Mesothelioma Resection Specimens
Institute, Egypt
PP01.54: Asbestos Consumption and Pleural
Mesothelioma Mortality in Poland
in Comparison with Other European
Countries
David Moore, University Hopsitals
Leicester NHS Trust, United Kingdom
PP01.64: Inherited Predisposition to Malignant
Mesothelioma
Anna Minkiewicz, Medical University of
Warsaw, Poland
Irma Dianzani, Interdepartmental Center
for Studies on Asbestos and other Toxic
Particulates “G. Scansetti”, Italy
PP01.56: Blood DNA Methylation Changes in
PP01.65: Characterization of Intertumor
Heterogeneity in Malignant
Mesothelioma
Elisabetta Casalone, Human Genetics
Foundation and University of Turin, Italy
Africa
Gill Nelson, University of Witwaterrand,
South Africa
Noushin Nabavi, Vancouver Prostate
Centre, Canada
PP01.66: Pathology Analysis for Mesothelioma
Study in the United Kingdom: Current
Practice and Historical Development
Bruce Case, McGill University, Canada
PP01.59: Malignant Pleural Mesothelioma Long
Term Survivors: A Population Based
Study (LUME Study)
PP01.67: Variations in Copy Number in the
Genome
Valeria Ascoli, Oncological and AnatomoPathological Sciences, Sapienza
University, Italy
PP01.60: Epidemiology of Mesothelioma in
Southern Brazil: A Reality Still to Be
Studied
Italy
Young People
Ahmed El Bastawisy, National Cancer
Institute, Egypt
Marieke Hylebos, Center for Oncological
Research, University of Antwerp,
Belgium
PP01.68: Homozygous 9p21 (p16/CDKN2A)
Deletion in Mesothelioma–5 Year
Retrospective Specialist Diagnostic
Pleural Pathology Audit
Lauren Harries, University Hospital of
South Manchester, United Kingdom
PP01.69: Mutation Status and Expression of the
microRNA-Processing RibonucleaseIII Dicer1 in Malignant Pleural
Mesothelioma
16
Austria
Eric Santoni-Rugiu, Copenhagen
University Hospital, Denmark
iMig2016.ORG
MONDAY, MAY 2
Sophie Sneddon, National Centre
for Asbestos Related Diseases, The
University of Western Australia, Australia
PP01.71: Mutational Burden and CDKN2A Status
as a Robust Outcome Predictor for
Radical Surgery in Mesothelioma
Annabel Sharkey, University of Leicester,
United Kingdom
PP01.72: Whole-Genome Dna Methylation and
Transcriptome Changes in Asbestos
Exposed met5a Cells
Elisabetta Casalone, Human Genetics
Foundation and University of Turin, Italy
PP01.73: Genomic Interrogation of a Clonal
Recurrence of Pleural Mesothelioma
12.5 Years After Radical Surgery
Annabel Sharkey, University of Leicester,
United Kingdom
PP01.77: A Systematic Investigation of the
Maximum Tolerated Dose of Cytotoxic
Chemotherapy with Supportive Care in
Mice
Willem Lesterhuis, National Centre
PP01.78: Cancer Chemo Immunotherapy Exploiting the Immunogenic Potential of
Cyclophosphamide
MONDAY, MAY 2
PP01.70: A Comparison of the Genetic
Characteristics of Murine and Human
PP01.79: Identification of Repurposed Drugs That
Increase Immune Checkpoint Blockade
Efficacy in Mesothelioma Using Network
Analysis of Responding Tumours
PP01.74: CDKN2A Deletion: A Clonal Mutation
in Malignant Pleural Mesothelioma
Development?
Luke Martinson, University of Leicester,
United Kingdom
PP01.75: Update: Recent Studies Examining
Impact of BAP1 Mutation on
Mesothelioma Risk and Implications for
Mesothelioma Litigation
Steven Kazan, Kazan McClain Satterley
& Greenwood, USA
PP01.76: BAP1 Value in Diagnosis
Cancer Center, USA
iMig2016.ORG
17
TUESDAY, MAY 3, 2016
EARLY INTERVENTIONS
08:00 – 08:45
10:20
ISS01: Industry-Supported Symposium
Hall 9
For the detailed programme please refer
to page 49.
10:30 – 11:15
Networking Break
and Poster Viewing
Hall 3
09:00 – 10:30
PL03: Plenary Session III:
The Knife or the Needle?
Chairs: Najib Rahman, United Kingdom &
David Waller, United Kingdom & Seiki
Hasegawa, Japan
Hall 1
18
09:00
PL03.01: The Evidence for Surgery
Joseph Friedberg, University of Maryland
School of Medicine, USA
11:15 – 12:45
PL04: Plenary Session IV:
From Genetics to Therapy
Chairs: Richard Lake, Australia & Harvey Pass,
USA & Paul Baas, Netherlands
Hall 1
11:15
PL04.01: Matching Drugs with Genes
Ultan McDermott, Wellcome Trust
Sanger Institute, United Kingdom
11:35
PL04.02: The Therapeutic Link
Between BAP1 and EZH2
Lindsay Lafave, Memorial Sloan
Kettering Cancer Center, USA
11:55
PL04.03: Phase 1 Study of
Tazemetostat (EPZ-6438), an Inhibitor
of EZH2, in Patients with NonHodgkin Lymphoma and Solid Tumors
09:20
PL03.02: The Evidence for
Chemotherapy
Jan Van Meerbeeck, University Hospital
Antwerp, Belgium
09:40
PL03.03: Debate: What Would You Do
First in Early Stage MPM Surgery or
Chemotherapy?
David Rice, MD Anderson Cancer Center,
USA
Peter Ho, Epizyme Inc., USA
Raja Flores, Mount Sinai Health System,
USA
12:05
Peter Szlosarek, Barts Cancer Institute
& St. Bartholomew’s Hospital, United
Kingdom
PL04.04: From Chaotic to Specific
Genomic Alterations
Sakari Knuutila, University of Helsinki,
Finland
Rolf Stahel, University Hospital Zürich,
Switzerland
Arnaud Scherpereel, Hospital of the
iMig2016.ORG
TUESDAY, MAY 3
PL04.05: Differential Response of
Cells to Yap Targeted Therapy
According to Molecular Classification
14:25
MS09.02: A New Prognostic Score
for Treatment Allocation for
Multimodality Therapy for Malignant
Pleural Mesothelioma - An Update
Robin Tranchant, INSERM U.1162,
France
12:35
PL04.06: Novel Synergistic Cell
Therapies for the Treatment of
14:35
MS09.03: Group Discussion Consensus on Patient Selection
Krishna Kolluri, University College
14:45
MS09.04: It’s Never Too Late To
Operate - An Analysis Of Salvage
Surgery For Progressing Malignant
Annabel Sharkey, University Hospitals of
14:55
MS09.05: Group Discussion Consensus on Timing of Surgery
15:05
MS09.06: Evolution of Surgical
Approach in Malignant Pleural
Mesothelioma
Seiki Hasegawa, Hyogo College of
Medicine, Japan
15:15
MS09.07: When Is Extrapleural
Pneumonectomy Necessary?
Walter Weder, University Hospital Zürich,
Switzerland
15:25
MS09.08: The Role of Pleurectomy/
Decortication in the Mesothelioma
Risk-Benefit Equation
Raja Flores, Mount Sinai Health System,
USA
15:35
MS09.09: Group Discussion Technical Points of Importance to
Obtain a Macroscopic Complete
Resection
12:45 – 14:15
Networking Break
and Poster Viewing
Hall 3
13:15 – 14:15
Hall 9
to page 49.
14:15 – 15:45
Surgery (Technical Aspects)
Chairs: Walter Weder, Switzerland & David
Waller, United Kingdom
Hall 6
14:15
MS09.01: Extended PleurectomyDecortication for Pleural
Mesothelioma in the Elderly - the
Need for an Inclusive yet Selective
Approach
TUESDAY, MAY 3
12:25
Annabel Sharkey, University Hospitals of
iMig2016.ORG
19
TUESDAY, MAY 3
14:15 – 15:45
TUESDAY, MAY 3
Novel Targets – Entering in the
Clinic
Chairs: Hedy Kindler, USA & Sanjay Popat,
United Kingdom
14:15
20
Hall 9
MS10.01: Phase I Study of AntiMesothelin Antibody Drug Conjugate
Anetumab Ravtansine in Patients
with Metastatic Mesothelioma
USA
14:25
MS10.02: Phase 1 Dose Expansion
Experience of ADI-PEG20,
Pemetrexed and Cisplatin in Patients
with Malignant Mesothelioma (TRAP
Study)
Peter Szlosarek, Barts Cancer Institute,
United Kingdom
14:35
MS10.03: Tremelimumab and
Durvalumab Combination for First
and Second-Line Treatment of
Mesothelioma Patients: The NIBITMESO-1 Study
15:05
MS10.06: Oncolytic Herpesvirus
Therapy for Mesothelioma - a Phase
I/IIa Trial of Intrapleural HSV1716
(NCT01721018)
Kevin Blyth, Queen Elizabeth University
15:15
MS10.07: A Phase I Clinical Trial
of HVJ-Derived Nanoparticle for
Chemotherapy-Resistant Malignant
Chunman Lee, Osaka University, Japan
15:25
MS10.08: Discussion
14:15 – 15:45
Critical Signaling Pathway
Chairs: Yoshitaka Sekido, Japan & Daniel
Murphy, United Kingdom & Anne Tsao,
USA
Hall 10a
14:15
MS11.01: Antagonizing the Hedgehog
Pathway with Vismodegib Impairs
Growth in Vivo by Affecting Stroma
Luana Calabro, University Hospital of
Siena, Italy
Mayura Meerang, University Hospital
Zurich, Switzerland
14:45
MS10.04: Phase 2 Neoadjuvant
Study of VS-6063, a FAK Inhibitor, in
Subjects with Surgically Resectable
14:25
MS11.02: SIRT1 at the Crossroads of
AKT1 and ERβ in Malignant Pleural
Mesothelioma Cells
USA
Laura Moro, University of Piemonte
Orientale, Italy
14:35
MS11.03: Evaluation of Sensitivity
to PI3K/mTOR and FAK Inhibition in
Pre-Clinical Models of Malignant
Mesothelioma
Ian Powley, MRC Toxicology Unit, United
Kingdom
14:55
MS10.05: Phase I Experience with
TargomiRs in Malignant Pleural
Mesothelioma
Nico Van Zandwijk, Asbestos Diseases
iMig2016.ORG
14:45
MS11.04: Identifying MicroRNAs With
Therapeutic Potential in Malignant
Glen Reid, Asbestos Diseases Research
Institute, Australia
14:55
MS11.05: MicroRNA-31 Regulates
Chemosensitivity in Malignant
Pleural Mesothelioma via Altered
Intracellular Drug Localisation
Hannah Moody, Hull York Medical
School, United Kingdom
15:05
MS11.06: Targeting the Rate-Limiting
Step of Protein Synthesis Overcomes
Chemoresistance in Malignant
Mesothelioma
Stefano Grosso, MRC Toxicology Unit,
United Kingdom
15:15
MS11.07: The Role of Monocyte
Chemotactic Protein-1 (MCP-1) in
Mesothelioma-Induced Malignant
Pleural Effusion Formation
Sally Lansley, Institute for Respiratory
Health, Australia
15:25
14:25
MS12.02: Simultaneous Care (SimC)
in Mesothelioma (MM): A Dedicated
Team to Prevent Urgent and
Unplanned Hospital Admissions
Federica Grosso, SS. Antonio e Biagio e
C. Arrigo, Hospital, Italy
14:35
MS12.03: Open Discussion Session
15:10
15:45 – 16:30
Networking Break
and Poster Viewing
Hall 3
16:30 – 18:00
Genomics and Drug Sensitivity
Chairs: Ultan McDermott, United Kingdom &
Marc Ladanyi, USA
TUESDAY, MAY 3
TUESDAY, MAY 3
Hall 10a
16:30
MS13.01: The MexTAg Collaborative
Cross: Identifying the Genetic Basis of
Mesothelioma
Treatment Advances in Peritoneal
Mesothelioma / Palliative Care for
All Mesothelioma
Scott Fisher, National Centre for
Asbestos Related Diseases, Australia
16:40
Chairs: Jeremy Steele, United Kingdom & Helen
Clayson, United Kingdom
MS13.02: Translational Control of
MPM: Role of eIf6 and MicroRNAs in
Metabolism
Stefania Oliveto, INGM - Fondazione
Istituto Nazionale Genetica Molecolare
“Romeo ed Enrica Invernizzi”, Italy
16:50
MS13.03: BAP1 Knockout by CRISPRCas9 Genome Editing in Malignant
Pleural Mesothelioma Cell Lines for
Isogenic Functional Studies
Julija Hmeljak, Memorial Sloan Kettering
Cancer Center, USA
14:15 – 15:45
Hall 10b
14:15
MS12.01: Gender and Menopausal
Status: Survival in Peritoneal
Mesothelioma
Gleneara Bates, Columbia University
Medical Center, USA
iMig2016.ORG
21
TUESDAY, MAY 3
MS13.04: BAP1 Expression and
Impact on Treatment Outcomes in
Malignant Pleural Mesothelioma in a
Prospective UK Based Clinical Trial
16:50
MS14.03: Overcoming Radiation
Resistance of Mesothelioma by
Activating Tumour Specific Cell Death
Neelam Kumar, University College
Lesley Gilmour, University of Glasgow,
United Kingdom
17:10
MS13.05: Relationship of PD-L1
Expression and Prognosis in
Epithelioid Mesothelioma
17:00
MS14.04: Synergistic Effect of
Local Radiation Therapy and
Immunotherapy in a Mouse Model of
MPM
Tohru Tsujimura, Hyogo College of
Medicine, Japan
Luis De La Maza-Borja, University Health
Network, Canada
17:20
MS13.06: Systems Biology
Approaches Towards Developing
Personalized Cancer Therapies for
(MPM)
17:10
MS14.05: The SMART Trial - an
RCT of Prophylactic Radiotherapy
in Preventing Procedure Tract
Metastases in Mesothelioma
Marija Krstic-Demonacos, University of
Salford, United Kingdom
Nick Maskell, University of Bristol,
United Kingdom
17:30
17:20
TUESDAY, MAY 3
17:00
16:30 – 18:00
Radiotherapy
Chairs: Noelle O’Rourke, United Kingdom &
Andreas Rimner, USA
16:30 – 18:00
Multimodality
Chairs: Paul Baas, Netherlands & Raphael
Bueno, USA
Hall 6
Hall 10b
22
16:30
MS15.01: Combined Modality
Treatment Using Extrapleural
Pneumonectomy for Malignant
Pleural Mesothelioma: A Single
Centre Experience
Keith Cengel, University of Pennsylvania,
USA
Philippe Nafteux, KU Leuven-University
of Leuven, Belgium
16:40
MS14.02: SYSTEMS-2:Randomised
Phase II Trial of Standard versus Dose
Escalated Radiotherapy for Pain in
16:40
MS15.02: Outcome of Trimodality
Therapy including Intracavitary
Hydrogen Peroxide Treatment in
Miranda Ashton, Beatson West of
Scotland Cancer Centre, United Kingdom
Austria
16:30
MS14.01: Examining Signaling
Pathway Crosstalk in Mesothelioma
PDT and RT Sensitivity Using 2D and
Novel 3D Tissue Culture Models
iMig2016.ORG
TUESDAY, MAY 3
MS15.03: Cytoreductive Surgery
and Hyperthermic Intrathoracic
Chemotherapy for Treatment of
Pleural Mesothelioma: A 10-Year
Experience
16:30
MS16.01: Blockade of Protein Kinase
A (PKA) Localization Augments
Trafficking And Anti-Tumor Efficacy
Of CAR T cells
Pietro Bertoglio, U.O. Chirurgia Toracica,
Italy
Edmund Moon, University of
Pennsylvania, USA
17:00
MS15.04: Radical Pleurectomy
and Hyperthermic Intrathoracic
Chemoperfusion for the Treatment of
16:40
MS16.02: Characterising T-Cell
Responses against Mutated
Mesothelioma Neo-Antigens
Laura Klotz, Center for Thoracic Surgery
Munich, Germany
16:50
17:10
MS15.05: Intracavitary CisplatinFibrin Application Following
Resection of Mesothelioma
MS16.03: CSF1R-Blockade
Synergizes with Dendritic Cell
Immunotherapy in a Mesothelioma
Preclinical Model
Floris Dammeijer, Erasmus Medical
Center, Netherlands
17:20
MS15.06: Pleurectomy / Decortication
and Intraoperative Intrapleural
Hyperthermic CDDP Perfusion for
17:00
MS16.04: Prostaglandin E2-cAMPAdenosine Nexus in Mesothelioma;
Self Amplifying Immunosuppression?
Zsuzsanna Tabi, Cardiff University,
United Kingdom
17:10
MS16.05: Heterotypic 3D Spheroid
Tumour Modeling of Mesothelioma to
Determine Immune Resistance
Saly Al-Taei, Cardiff University, United
Kingdom
17:20
MS16.06: Immune Escape Correlates
Strongly with an Inflamed Phenotype
in Malignant Mesothelioma
Yi-Hung Carol Tan, University of Chicago,
USA
17:30
MS16.07: Exploiting Immune
Checkpoint Blockade to Develop
Effective Therapy for Malignant
Mesothelioma
Asbestos Related Diseases, Australia
17:40
Kenichi Okubo, Tokyo Medical and
Dental University, Japan
17:30
MS15.07: HIPEC as a Treatment for
Malignant Peritoneal Mesothelioma:
Are We There Yet?
Gleneara Bates, Columbia University
Medical Center, USA
17:40
16:30 – 18:00
Novel Immune Strategies
Chairs: Bruce Robinson, Australia & Joachim
Aerts, Netherlands & Dan Sterman (USA)
Hall 9
iMig2016.ORG
TUESDAY, MAY 3
16:50
23
TUESDAY, MAY 3
18:00 – 19:30
PP02: Poster Mixer with Poster
Discussions 2
TUESDAY, MAY 3
Moderators: David Waller, United Kingdom &
Noelle O’Rourke, United Kingdom
& Takashi Nakano, Japan & Peter
Szlosarek, United Kingdom & Paul Baas,
Netherlands & Ian Woolhouse, United
Kingdom & Rabab Gaafar, Egypt &
Mary Hesdorffer, USA & Robert Rintoul,
United Kingdom & Sanjay Popat, United
Kingdom & Gary Middleton, United
Kingdom
Hall 3
PP02.01: Art and Science: Relationship with
Human Anatomy from Aesthetic and
Scientific Perspectives
Guillermo Villamizar, FundClas,
Colombia
PP02.02: Localized Splenic Reoccurrence in
Malignant Peritoneal Mesothelioma
Yaakov Bressler, Columbia University
Medical Center, USA
PP02.03: Radiological Features of Pleural
Mesothelioma Compared with Cases
Diagnosed before and after 2008 in
Japan
Katsuya Kato, Kawasaki Medical School,
Japan
PP02.05: Asbestos Body and Pleural Plaque
of Patients with Malignant Pleural
Mesothelioma Who Underwent
Extrapleural Pneumonectomy
24
Kazunori Okabe, Yamaguchi Ube Medical
Center, Japan
Vincent Lam, University Hospitals of
PP02.07: Patterns of Detectable Tumor
Progression in Patients with Malignant
Pleural Mesothelioma with an FDG-PETNegative T1a Tumor
Kozo Kuribayashi, Hyogo College of
Medicine, Japan
PP02.08: Lymphangitic Carcinomatosis: A
Common Form of Progression in
Following Radical Pleurectomy
Ian Berger, University of Pennsylvania,
USA
PP02.09: Malignant Pleural Mesothelioma,
Demographic Data and Clinical Staging
of 193 Consecutive Patients
Amr Eldemery, National Cancer Institute,
Egypt
PP02.10: Into the Deep: Closer Look at Immune
Cells and Immune Checkpoint
Expression in Human Malignant Pleural
Mesothelioma
Takumi Kishimoto, Okayama Rosai
Hospital, Japan
PP02.04: CT Findings of Malignant Pleural
Mesothelioma and Correlation with the
Survival Period
PP02.06: The Imaging Journey of a Patient with
Elly Marcq, Center for Oncological
Research, University of Antwerp,
Belgium
PP02.11: Development of Novel Therapeutics
Targeting Malignant Pleural
Mesothelioma
Perry Devo, University of Greenwich,
United Kingdom
PP02.12: Inhibition of Methyltransferase EZH2
Improves Tumoricidal Activity of
Macrophages against Mesothelioma
Cells
Malik Hamaidia, Interdisciplinary Cluster
for Applied Genoproteomics (GIGA) of
University of Liège, Belgium
iMig2016.ORG
TUESDAY, MAY 3
PP02.21: Focal Adhesion Kinase Inhibition Targets
Macrophages in vitro and in vivo in a
Mesothelioma Mouse Model
Carmelina Iannuzzi, University of Siena,
Italy
PP02.14: Characterising CTL Responses against
Mesothelioma Neo-Antigens
PP02.22: Pleural Effusion of Patients with
Malignant Mesothelioma Induces
Macrophage-Mediated T Cell
Suppression
PP02.15: Gene Profile of Mesothelioma
Tumorigenesis and Initiation after
Chemoradiation Treatment in vitro and in
vivo Models
Licun Wu, Toronto General Hospital
and Princess Margaret Cancer Center,
Canada
PP02.16: The Elevated Levels of G-MDSC in
Mesothelioma Patients Inhibit T Cell
Proliferation and Function by ROS
Generation
Licun Wu, Toronto General Hospital
and Princess Margaret Cancer Center,
Canada
Asbestos Related Diseases. The
PP02.27: Legal Claims for Asbestosis in the
Netherlands Possible since 2014: How
It Works
Wanda Hagmolen Of Ten Have,
Radboudumc, Netherlands
PP02.28: Evaluation of Curcumin i.p. For
the Treatment of Sarcomatoid
Mesothelioma, Experimental Study on a
Rat Model
Daniel Pouliquen, UMR 892 INSERM /
6299 CNRS, France
PP02.29: Biphasic Pleural Mesothelioma: Unusual
Clinical Behavior
Abdulhadi Almutairi, King Fahad
Specialist Hospital, Saudi Arabia
PP02.30: MARS 2: A Feasibility Study Comparing
(Extended) Pleurectomy Decortication
versus No Pleurectomy Decortication
iMig2016.ORG
Alistair Cook, The University of Western
PP02.26: Targeted Depletion of Regulatory T Cells
in Mesothelioma
Matthew Wu, University Health Network,
Canada
PP02.19: Immunophenotype of a Novel Murine
Mesothelioma Cell Line RN5 and Specific
Immunity Generated by Pulsation with
Cell Lysate
Adrian Dobbs, University of Greenwich,
United Kingdom
PP02.18: HMGB-1 Release and the CD8+ T
Cell Response Elicited by Radiation
Treatment in Malignant Pleural
Mesothelioma
Lysanne Lievense, Erasmus MC Cancer
Institute, Netherlands
PP02.23: The Abscopal Effect of Radiotherapy in
the Context of Checkpoint Blockade in a
Mouse Mesothelioma Model
USA
PP02.17: Novel Medicinal Chemistry Approaches
in Mesothelioma: The Role of Natural
Products
Lysanne Lievense, Erasmus MC Cancer
TUESDAY, MAY 3
PP02.13: The Dl 922-947 Oncolytic Virus as a
New Possible Therapeutic Tool against
Mesothelioma
Eric Lim, Royal Brompton Hospital,
United Kingdom
25
TUESDAY, MAY 3
PP02.39: Does Open Access Expert Phone Triage
Based on 2012 IMiG Guidelines for
Veterans Receiving Care within the VA,
Alter Therapy?
TUESDAY, MAY 3
PP02.31: MesoTRAP: A Feasibility Study of
Indwelling Pleural Catheter versus
VAT Pleurectomy for Trapped Lung in
Mesothelioma
Robert Rintoul, Papworth Hospital NHS
PP02.32: LUME-Meso: A Placebo-Controlled
Phase II/III Study of Nintedanib +
Pemetrexed/Cisplatin Followed by
Maintenance Nintedanib
Sanjay Popat, Royal Marsden Hospital
NHS Foundation Trust, United Kingdom
PP02.33: Autologous Dendritic Cell
Immunotherapy Loaded with an
Allogenic Tumor Cell Lysate in Patients
with Mesothelioma
Joachim Aerts, Erasmus MC Cancer
PP02.34: Randomised Phase II Trial of Vinorelbine
as 2nd-Line Therapy for Patients with
Malignant Pleural Mesothelioma - VIM
Trial
Lisette Nixon, Cardiff University, United
Kingdom
PP02.35: A Randomized Study of Amatuximab
with Pemetrexed and Cisplatin as FrontLine Therapy for Subjects with Pleural
Mesothelioma
Bruce Wallin, Morphotek, Inc, USA
PP02.36: Switch-Maintenance with Gemcitabine
for Patients with Malignant
Mesothelioma: Feasibility of a
Randomized Phase II Study
Josine Quispel-Janssen, Netherlands
Cancer Institute, Netherlands
PP02.37: MESOCLIN: A French National Network
of Expert Centers for the Management
of MPM Patients and for Research
Promotion
26
Abraham Lebenthal, Brigham and
Women’s Hospital, USA
PP02.41: MINE PROJECT - Mesothelioma
Information Network in Europe
Corrado Magnani, University Eastern
Medicine, Italy
PP02.42: Personalised Support for Patients with
Malignant Pleural Mesothelioma (MPM)
in New South Wales, Australia
Jocelyn McLean, Asbestos Diseases
PP02.43: Surgical Cytoreduction and
Hyperthermic Intrathoracic
Chemotherapy (HITHOC) for Malignant
Michael Ried, University Medical Center
Regensburg, Germany
PP02.44: Diode-Pumped Nd:YAG Laser for LungSparing Surgical Treatment of Malignant
Pleural Mesothelioma - First Experience
Servet Bölükbas, Helios Klinikum
Wuppertal, Germany
PP02.45: Pathological Evaluation of the
Visceral Pleura Stamp in the Radical
Pleurectomy/Decortication for MPM
Patients
Masashi Kobayashi, Tokyo Medical and
Dental University, Japan
PP02.46: Clinical and Immunologic Impact
of Surgery for Malignant Pleural
Mesothelioma
Vincenzo Ambrogi, Tor Vergata
University, Italy
iMig2016.ORG
PP02.47: Who Benefits From Macroscopic
Complete Resection In Malignant Pleural
Mesothelioma?
PP02.54: Analysis of Gene-Expression Changes in
3D Spheroids Highlights a Survival Role
for ASS1 in Mesothelioma
Hasan Batirel, Marmara University
Faculty of Medicine, Turkey
PP02.48: Is Surgery For Mesothelioma In The UK
A Dying Modality In The Management Of
Malignant Mesothelioma? Update on our
Experience
PP02.55: Myosin II-Dependent Cell Contractility
Drives Spontaneous Nodule Formation of
Mesothelioma Cells
Mohammed Khalil, Castle Hill Hospital,
United Kingdom
PP02.49: The Analysis of the Recurrence of the
Patients Who Underwent Surgical
Resection for Malignant Pleural
Mesothelioma
Nobuyuki Kondo, Hyogo College of
Medicine, Japan
Courtney Broaddus, University of
California San Francisco, USA
Julia Tarnoki-Zach, Eotvos Lorand
University, Hungary
PP02.56: Post-Transcriptional Regulation of
Calretinin Expression
Jelena Kresoja-Rakic, University of
PP02.57: Identification of Cis- and TransActing Elements Regulating Calretinin
Expression in Mesothelioma Cells
PP02.50: Ipsilateral Pneumonectomy after
Pleurectomy/Decortication in a Patient
with Malignant Pleural Mesothelioma
PP02.58: Decreased Proliferation and Cell
Migration of Primary Mesothelial Cells
from Calretinin-Deficient (CR-/-) Mice
Toru Nakamichi, Hyogo College of
Medicine, Japan
Jelena Kresoja-Rakic, University of
PP02.51: Induction Chemotherapy Followed
by Surgery for Malignant Pleural
Mesothelioma
PP02.59: KCNMA1 Is Targeted by miR-17-5p and
Modulates Cell Migration in Malignant
Nobuyuki Kondo, Hyogo College of
Medicine, Japan
Walter Blum, University of Fribourg,
Switzerland
PP02.52: Anti-Tumor Effects of Metformin
and Nutlin-3a in Malignant Pleural
Mesothelioma
PP02.60: Engineered, Light-Controlled Growth
Factor Receptors for Mesothelioma
Research
Yuji Tada, School of Medicine Chiba
University, Japan
Yuen Yee Cheng, Asbestos Diseases
PP02.53: Compared High-Resolution Whole
Genome Screening of Mesothelioma and
Benign Asbestos Pleurisy
PP02.61: Preclinical Investigation of the
Therapeutic Potential of Nintedanib in
Tunç Tuncel, Eskisehir Osmangazi
University, Turkey
iMig2016.ORG
TUESDAY, MAY 3
TUESDAY, MAY 3
Michael Grusch, Medical University of
Vienna, Austria
Viktoria Laszlo, Medical University of
Vienna, Austria
27
TUESDAY, MAY 3
PP02.69: Trabectedin Is Active as Single Agent
and Synergizes with Chemotherapy and
Bcl-2 Inhibition in Malignant Pleural
Mesothelioma
TUESDAY, MAY 3
PP02.62: Comparative Analysis of 4 Experimental
Mesotheliomas in F344 Rats: A
Preliminary Study of Their Tumor Biology
Features
Joëlle Nader, UMR 892 INSERM / 6299
CNRS, France
PP02.63: THBS2, a Novel Gene Involved in
the Malignant Progression of Pleural
Mesothelioma
PP02.70: Live Cells Mesothelioma Biobank
to Explore Mechanisms of Tumor
Progression
Elisa Barone, University of Pisa, Italy
PP02.64: Growth Factor-Induced Morphology
and Expression Changes in Cell Models
Reflecting the Histological Mesothelioma
Subtypes
Masatoshi Tagawa, Chiba Cancer Center
Research Institite, Japan
PP02.67: Shed Syndecan-1 Alters Angiogenesis in
Katalin Dobra, Karolinska Institutet,
Sweden
PP02.68: Utilising MicroRNAs to Sensitise
Mesothelioma to Cisplatin and
Gemcitabine
Antonios Sideris, Brigham and Women’s
USA
PP02.72: Cell Assays and SAXS Indicate That
BAMLET Is a Potential Treatment for
Chemotherapy-Resistant Mesothelioma
Giulia Pinton, University of Piemonte
Orientale, Italy
PP02.66: Combination of Nutlin-3a and HSP90
Inhibitors Produces Synergistic
Cytotoxicity on Mesothelioma with the
Wild-Type p53
Emanuela Felley-Bosco, Zürich
University Hospital, Switzerland
PP02.71: Analysis of Novel RHOA Mutations in
Michael Grusch, Medical University of
Vienna, Austria
PP02.65: The H3K27me3 Demethylase KDM6B
as an Epigenetic Regulator of ER?
Expression in Human Malignant Pleural
Mesothelioma
28
Austria
Glen Reid, Asbestos Diseases Research
Institute, Australia
PP02.73: Tumour Suppressor microRNA-137-3p
Targets Onco-Protein YB-1 in Malignant
Thomas Johnson, Asbestos Diseases
PP02.74: IFN Regulatory Factor 9 Play Key Role in
Mesothelioma Growth
Yidan Zhao, University Health Network,
Canada
PP02.75: Pro-Oncogenic Effects of Pathogenic
Fibres on Mesothelial Cells
Joaquin Zacarias-Cabeza, MRC
Toxicology Unit, United Kingdom
Yuen Yee Cheng, Asbestos Diseases
iMig2016.ORG
TUESDAY, MAY 3
Hannah Ball, Oxford University Hospitals
PP02.77: “Around Australia in 80 Days”
Judy Rafferty, Canberra Hospital/Lung
Foundation Australia, Australia
iMig2016.ORG
TUESDAY, MAY 3
PP02.76: ‘Are the Psychological Needs of Patients
with Mesothelioma the Same as Those
with Advanced Lung Cancer?’
29
WEDNESDAY, MAY 4, 2016
NOVEL TREATMENT STRATEGIES & PALLIATION
08:00 – 08:45
10:00
PL05.05: Randomized Phase II
Study of Adjuvant WT1 Vaccine for
(MPM) After Multimodality Therapy
Marjorie Zauderer, Memorial Sloan
10:10
PL05.06: Improved Quality of Life in
Patients Undergoing Pleurectomy
and Decortication for Malignant
Wickii Vigneswaran, Loyola University
Medical Center, USA
10:20
Hall 6
to page 49.
09:00 – 10:30
PL05: Plenary Session V:
What is in the Locker Now?
Chairs: Craig Stevens, USA & Takashi Nakano,
Japan & Hedy Kindler, USA
Hall 1
09:00
Andreas Rimner, Memorial Sloan
09:10
PL05.02: Pneumonitis Predictors
in Intensity Modulated Radiation
Treatment of Mesothelioma Patients
with Two Lungs
30
PL05.01: Phase II Study on Intensity
Modulated Pleural Radiation Therapy
(IMPRINT) for Malignant Pleural
Mesothelioma: Final Results
Andrew Jackson, Memorial Sloan
09:20
PL05.03: Novel Combinations plus
Chemotherapy
09:40
PL05.04: State of the Art Approach to
Fluid Management
Nick Maskell, University of Bristol,
United Kingdom
10:30 – 11:15
Networking Break
and Poster Viewing
Hall 3
11:15 – 12:45
PL06: Plenary Session VI:
The “Immune War” on
Mesothelioma
Chairs: Ken O’Byrne, Australia & Luciano Mutti,
United Kingdom & Rabab Gaafar, Egypt
Hall 1
11:15
PL06.01: Targeting Mesothelin
USA
11:30
PL06.02: “Programmed to Kill” (CellBased Therapy)
Joachim Aerts, Erasmus Medical Center,
Netherlands
iMig2016.ORG
WEDNESDAY, MAY 4
PL06.03: Tartgeting Mutations to
Penetrate the Immune Shield
14:10
SS03.03: Career Opportunities:
Mentoring New Investigators
Marie-Claude Jaurand, INSERM UMR-S
1162, France
12:00
PL06.04: “Checking It Out” (Immune
Checkpoint Blockade)
14:30
Hedy Kindler, University of Chicago
Medical Center, USA
SS03.04: Open Discussion:
New Approaches to Translational
Research
Discussants:
Marion MacFarlane, United Kingdom &
Annabel Sharkey, United Kingdom
• Current and Future Directions of
Mesothelioma Research Bench to Bedside and Back Again
• Practical Challenges: e.g. Preclinical
Models- in vivo/ex vivo Models, Access
to Patient Samples, Bioinformatic
Analysis
12:15
PL06.05: The Immune Landscape
of Human Mesothelioma to Predict
Response to anti-PD1 Therapy
Astero Klabatsa, University of
Pennsylvania, USA
WEDNESDAY, MAY 4
11:45
12:25
PL06.06: Maximizing the “Immune
Attack”
Anna Nowak, University of Western
• Priority Research Areas for Funders
in the Mesothelioma Domain
12:40
15:00
SS03.05: Networking for
Development of New Collaborations
and Visits between Labs**
Introducing Opportunities Available for
up to 3 Months at These Institutions
• University of Eastern Piedmont Amedeo Avogadro Laura Moro, Italy
• MRC Toxicology Unit Marion MacFarlane, United Kingdom
• The University of Western Australia - Anna Novak, Australia
• University of California San Francisco - Courtney Broaddus, USA
• University of Leicester,
CRUK Leicester Centre
12:45 – 13:15
Presidential Closing
and Invitation to iMig 2018
Hall 1
13:30 – 15:30
SS03: Young Investigator’s Session*
Chair: Sara Busacca, United Kingdom
Hall 9
13:30
Industry
Nikki Roebuck, Clovis Oncology, United
Kingdom
• INSERM UMR-S 1162, Paris Didier Jean, France
• INSERM UMR 892, Nantes Marc Grégoire, France
13:50
Clinic & Research
Aaron Mansfield, Mayo Clinic, USA
*The Scientific Committee welcomes all Young
Investigators with a maximum of 10 years of experience.
**Visitors should be self-funded.
iMig2016.ORG
31
INFORMATION FOR INVITED SPEAKERS
AND ABSTRACT PRESENTERS
SPEAKER READY ROOM
The Media Suite at the ICC is the designated
Speaker Ready Room. All presenters are required to
submit and/or preview their slides at least 3 hours
prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.
Computers are available to upload and preview
presentations. Speakers are required to report to
the Speaker Ready Room at least 3 hours prior
to their scheduled presentations. Changes can
be made until 90 minutes prior to your presentation.
Presenters should make sure all fonts appear as expected and all sound/video clips are
working properly. The final version must be submitted to the Speaker Ready Room,
no file submissions are accepted in the Session Rooms.
Speaker Ready Room Opening Hours
Sunday, May 1
16:00 – 19:30
Monday, May 2
07:30 – 17:00
Tuesday, May 3
07:30 – 17:00
Wednesday, May 4
07:30 – 11:00
ORAL ABSTRACT
PRESENTERS
Oral Abstract Presenters are required to
prepare a PowerPoint Presentation for
their 10 minute didactic presentation
(max. 10 slides including title, author
and disclosure slides). Please make
sure that you stick to your allocated time.
The Conference chair will cut you off after
your allocated 10 minutes time slot!
32
POSTER PRESENTERS
All Poster Presentations/Boards are located
in Hall 3 at the ICC. A sign identifies each
Poster Board with the assigned Poster Number and the Presenter’s Name. The Poster
Board Number corresponds with the pre-assigned Final Presentation Number provided
in your confirmation letter and used in the
Abstract Book and this Onsite Programme.
Poster Presenters are required to provide a
2 minute presentation of their poster to the
invited Poster Moderators during the Poster
Mixer and Poster Discussion Session.
iMig2016.ORG
Please note that Poster Presenters will not
be asked to prepare a PowerPoint Presentation.
POSTER PRINTING
Poster Presenters are able print their posters onsite in the Graphics Studio (around
the corner from the Media Suite/Speaker
Ready Room). The cost of poster printing
is £30.00 per poster plus VAT. Delegates
must bring a USB stick with their presentation saved as a print quality PDF.
Poster Set-Up Time
Sunday, May 1, 2016
16:00 – 18:00
Poster Take-Down Time
Wednesday, Monday 4, 2016
12:00 – 14:30
Any posters not removed after
Take-Down Time will be removed
and discarded by management.
Poster Session 1
Monday, Monday 2, 2016
Poster Display Hours: 10:30 – 19:30
Meet the Author:
10:30 – 11:15
12:45 – 14:15
15:45 – 16:30
Mixer and Discussion: 18:00 – 19:30
Poster Session 2
Tuesday, Monday 3, 2016
Meet the Author: 10:30 – 11:15
12:45 – 14:15
15:45 – 16:30
Poster Session 3
Poster Display Hours:
Meet the Author: iMig2016.ORG
10:30 – 12:00
10:30 – 11:15
33
iMig2016.ORG
35
CONFERENCE VENUE
CONFERENCE INFORMATION
The International Convention Centre
(ICC)
Broad Street, Birmingham, B1 2EA
United Kingdom
www.theicc.co.uk
FLOOR PLANS
All iMig 2016
Conference
Session Rooms
as well as
Exhibits, Posters
and Registration
are located in
the International
Convention
Centre (ICC)
which is linked
directly to The
Hyatt Regency
Birmingham
via a covered,
secured bridge
link walkway.
LEVEL 5
EXECUTIVE ROOM 1
iMig BOARDROOM
EXECUTIVE ROOM 2
MEETING ROOM
LEVEL 4
HALL 3
HALL 1
PLENARY HALL
EXHIBITS & POSTERS
LUNCH & NETWORKING
BREAKS
REGISTRATION
MEDIA SUITE
SPEAKER READY ROOM
& MEDIA OFFICE
LEVEL 3
HALL 6
SESSION ROOM
LEVEL 2
HALL 10A / 10B
HALL 9
SESSION ROOMS
SESSION ROOM
iMig2016.ORG
37
GENERAL INFORMATION FROM A TO Z
Abstract Book (USB Stick)
All accepted and confirmed abstracts
are available on the Conference website
at www.iMig2016.org and on a USB Stick
handed out with your registration materials.
International Attendees can request and
pick up a ‘Certificate of Attendance’ at
Registration during regular registration
hours. Please note that registration closes
at 11:00 on Wednesday, May 4.
SUPPORTED BY
Charging Stations
Badges
Your personalised badge is your admission
card to the congress. For organisational
and security reasons, badges must be
worn at the congress venue at all times.
A lanyard will be given to you with the congress bag. In case of loss, a replacement
badge will be provided at an administrative
charge of £25.00.
LANYARDS/BADGE HOLDERS
SUPPORTED BY
Birmingham Information
Maps and a brochure of Birmingham are
available at Registration.
Cameras and Cell Phones
No cameras or video cameras are allowed
in any event during iMig 2016. As a courtesy to fellow delegates, please turn off cell
phones during scientific sessions.
Certificate of Attendance
To complete the session evaluation and
obtain credits for your attendance at iMig
2016, please use the online evaluation
system at iMig2016.org.
38
Charging Stations will be available in the
Exhibit Hall (Hall 3) to allow you to take a
break while powering your mobile devices.
SUPPORTED BY
CME Credit Allowance
The International Mesothelioma Interest
Group (iMig) is accredited by the European Accreditation Council for Continuing
Medical Education (EACCME) to provide
the following CME activity for medical specialists. The EACCME is an institution of
the European Union of Medical Specialists
(UEMS), www.uems.net.
iMig 2016 will be accredited with 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing
Medical Education (EACCME).
Through an agreement between the
European Union of Medical Specialists and
the American Medical Association, physicians may convert EACCME credits to an
equivalent number of AMA PRA Category
1 Credits™. Information on the process to
convert EACCME credit to AMA credit
can be found at www.ama-assn.org/go/
internationalcme.
iMig2016.ORG
Delegate Help Desk
If you require assistance or any information regarding the Conference, see the
staff at the Delegate Help Desk located in
the Registration area of the ICC.
SUPPORTED BY
Monday, May 2
Networking Break
10:30 – 11:15
Lunch
LUNCH SUPPORTED BY
12:45 – 14:15
Networking Break 15:45 – 16:30
Exhibition
The Exhibition is located in Hall 3 at the
International Convention Centre (ICC).
Please find a floor plan of the exhibition
and a detailed list of all exhibitors on
page 54.
Tuesday, May 3
Networking Break
10:30 – 11:15
Exhibition Opening Hours
Lunch
12:45 – 14:15
Sunday, May 1
18:30 – 21:30
(Opening Networking Reception)
Networking Break 15:45 – 16:30
Monday, May 2
10:30 – 19:30
Tuesday, May 3
10:30 – 19:30
Wednesday, May 4
10:30 – 12:00
Wednesday, May 4
Networking Break
10:30 – 11:15
Onsite Mobile Application
Lost and Found
Lost and Found items should be returned/
claimed at the Registration and Foyer Area
at the ICC.
Networking Breaks & Lunches – Hall 3
(Exhibition & Posters)
During the Conference, refreshments and
snacks will be provided for registered
delegates in Hall 3.
iMig2016.ORG
Plan your personalized iMig 2016 Conference schedule. Browse sessions by track,
date, and time. The mobile application
includes all abstracts submitted and
accepted for the iMig 2016 Conference.
Sync with your Outlook calendar and many
more. Get local information and the weather forecast for the next 5 days. Available
for iPhone, iPad, Android. Download the
app from www.iMig2016.org.
SUPPORTED BY
39
Parking
The nearest car parks to the ICC are
located at the Barclaycard Arena. Current
charges are from £2.30 for up to 2 hours to
£8.00 for 24 hours. Payment can be made
by coin or card at the Pay and Display
machines. Alternative parking is located at
Brindleyplace or Paradise Circus.
Poster Session 3
Poster Display Hours:
10:30 – 11:15
Press & Media Room
Poster Sessions
The Poster Sessions will be held in the
Exhibit Area. For detailed information
on Posters displayed please refer to the
Programme pages.
Poster Session 1
Monday, Monday 2, 2016
Meet the Author:
10:30 – 11:15
12:45 – 14:15
15:45 – 16:30
Poster Session 2
Tuesday, Monday 3, 2016
SUPPORTED BY
12:45 – 14:15
15:45 – 16:30
iMig2016.ORG
The Media Suite on Level 4 at the ICC is
the designated Press & Media Room.
Press and Media passes are issued to
individuals representing a recognized
news organization, including freelancers
who contribute to such organizations.
Individuals involved with public relations,
marketing sales, circulation, advertising,
or any other non-editorial function are NOT
eligible for press passes. Press and Media
representatives are required to check in
at the Registration Counter. Media Press
credential is required to receive a Press/
Media Badge.
Press & Media Room Opening Hours
Monday, May 2
07:30 – 17:00
Tuesday, May 3
07:30 – 17:00
Wednesday, May 4
07:30 – 11:00
Internet access and a printer are available
in the Media Room to assist credentialed
media representatives.
Public Transportation
By Public Transit
Network West Midlands provides city transit for tourists and residents seven days a
week via Bus, Train and Metro.
41
By Car
Birmingham’s city centre is partially
pedestrianised and has several unintuitive
one-way systems. Expect to pay £1 – £1.50
per hour in Pay & Display areas and more
on street meters. Parking attendants patrol
popular areas regularly, so expect a fine if
you return late or a clamp if you’re parked
illegally.
By Taxi
Birmingham has an abundance of taxi
ranks all over the city, the best-served
being New Street Station. Both hackney
carriages and private hire vehicles are easy
to find, but you should exercise caution
and not get into an unmarked car or one
you haven’t booked.
By Train
Birmingham has a single metro line, running
between Snow Hill Station and Wolverhampton, via the Jewellery Quarter, West Bromwich, Wednesbury and Bilston. The Metro
runs from roughly 06:30 – 23:30 Monday
to Saturday, and 08:00 – 23:00 Sunday and
bank holidays. Fares vary with distance, but
expect to pay around £2 for a single, £3.50
for a return and £4.50 for a day pass.
By Foot
Birmingham’s City Centre is partially
pedestrianised, and most things to see and
do can be reached on foot.
Registration Counter Hours
iMig 2016 Registration is located on the
Registration and Foyer Area at the ICC.
Sunday, May 1
16:00 – 21:00
Monday, May 2
07:30 – 17:00
Tuesday, May 3
07:30 – 17:00
Wednesday, May 4
07:30 – 11:00
Smoking
Smoking is prohibited in all areas of the
Hyatt Regency Birmingham and the ICC.
Speaker Ready Room
The Media Suite at the ICC is the designated Speaker Ready Room. All presenters
are required to submit and/or preview their
slides at least 3 hours prior to their scheduled presentation to ensure compatibility
with the Conference AV Equipment.
Staff and Volunteers
Volunteers are happy to assist with any
questions delegates may have regarding
the Conference or the International Convention Centre. Delegates can easily locate
them by their staff/volunteer shirts.
SUPPORTED BY
Wireless Internet
Wireless Internet is available throughout
the ICC.
GENEROUSLY SUPPORTED BY
DISCLAIMER
The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility
for changes of the Programme or any loss that may occur as a result of changes of the Programme. Some of the information provided in
this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
42
iMig2016.ORG
AWARDS
44
IMIG WAGNER MEDAL
IMIG RESEARCH AWARD
The iMig Wagner Medal will be awarded during the Gala Dinner.
The iMig Research Award will be
awarded during the Gala Dinner.
J. Christopher Wagner was a leader in the
field of Mesothelioma who made major
contributions to the understanding of
Mesothelioma, its cause and the goals for
prevention. By his clinical observations
and animal studies, he was the first to
establish that Mesothelioma was caused
by asbestos. Inspired by this example, the
International Mesothelioma Interest Group
presents the Wagner Medal every two
years to an individual who has made major
original contributions to the understanding
of Mesothelioma, either in basic or applied
research. It is the highest honour presented by the International Mesothelioma
Interest Group to a leader in the field.
The iMig Research Awards will be awarded
every two years to recognize the potential
significance and impact on the field of novel mesothelioma research (basic, translational, or clinical) that has been published
or presented since the prior International
Conference of the International Mesothelioma Interest Group. Research to be
presented during the current Conference
would qualify an investigator for the iMig
Research Awards.
2002 Marie-Claude Jaurand
PhD, France
2004
Bruce Robinson, MD, Australia
The iMig Service Award may be awarded
every two years to an individual who has
made significant and sustained contributions of service to the mission of the International Mesothelioma Interest Group.
2006
Harvey Pass, MD, USA
2008
Brooke Mossman, PhD, USA
2010
Steven Albelda, MD, USA
2012
Joseph R. Testa, PhD. USA
2014
Raffit Hassan, MD, USA
IMIG SERVICE AWARD
The iMig Service Award will be awarded during the Gala Dinner.
iMig2016.ORG
BEST INVESTIGATOR AWARDS
The Best Investigator Award Recipient will receive their award during the Presidential Closing.
Edmund Moon, USA
MS16.01:Blockade of Protein Kinase A (PKA)
Localization Augments Trafficking And Anti-Tumor Efficacy Of CAR T Cells
YOUNG INVESTIGATOR AWARDS
SUPPORTED BY
Young Investigator Award Recipients will receive their awards during the Presidential Closing.
Hannah Moody, United Kingdom
Floris Dammeijer, Netherlands
MS11.05: MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma via Altered Intracellular Drug Localisation
MS16.03: CSF1R-Blockade Synergizes with
Dendritic Cell Immunotherapy in a Mesothelioma Preclinical Model
Rossella Bruno, Italy
Kevin Lamote, Belgium
MS08.04: Digital Gene Expression Profiling
to Separate Malignant Pleural Mesothelioma
from Benign Reactive Mesothelial Hyperplasia
MS05.02: Haptoglobin Phenotype Is a Risk
Factor for Malignant Pleural Mesothelioma
Marissa Williams, Australia
MS04.03: Tumour Suppressor microRNAs
Regulate PD-L1 Expression in Malignant
DEVELOPING NATIONS TRAVEL GRANTS
SUPPORTED BY
Developing Nations Travel Grant Recipients will receive their awards
during the Presidential Closing.
Ahmed El Bastawisy, Egypt
PP01.61: Malignant Pleural Mesothelioma
in Young People
iMig2016.ORG
Hala Aziz Shokralla, Egypt
PP01.29: Does Malignant Pleural Mesothelioma with Metastases at First Presentation Really Benefit from Chemotherapy?
45
SPECIAL WORKSHOP
SPECIAL WORKSHOP
Sunday, May 1
12:30 – 18:00
14:45
SS01.06: The Difference between the
Psychological Care Needs for Those
with Lung Cancer and Mesothelioma A Review of the Literature
Hannah Ball, Oxford University Hospitals
15:15
SS01.07: Afternoon Tea
16:00
SS01.08: Top Tips for Symptom
Management in Mesothelioma
Karen Lord, University Hospitals of
16:30
SS01.09: A Global Overview of Clinical
Trials in Mesothelioma (Pleural and
Peritoneal)
Mary Hesdorffer, Mesothelioma Applied
Research Foundation, USA
17:00
SS01.10: Taking Mesothelioma
‘On the Road’
Judy Rafferty, Lung Foundation Australia,
Australia
17:30
SS01.11: Key Messages and
Campaigns
Melinda Kotzian, Mesothelioma Applied
Research Foundation, USA & Laurie
Kazan-Allen, British Asbestos Newsletter,
United Kingdom
Mesothelioma Nurse Meeting
Location: The Sonata Room,
Hyatt Regency Birmingham
12:30
SS01.01: Networking Opportunity
13:00
SS01.02: Welcome
Kingdom & Vanessa Beattie, Aintree
University Hospital, United Kingdom
13:15
SS01.03: Nursing Care for
Mesothelioma Patients Receiving
Immunotherapy
Michelle Turner, Maryland Proton
Therapy Center, USA
13:45
SS01.04: What is in a ‘Living with
Meso’ Toolkit
Natalie Doyle, Royal Marsden, United
Kingdom
14:15
SS01.05: A Coordinated Approach
to Setting up and Managing a
Comprehensive Mesothelioma
Service
Melissa Culligan, University of Maryland,
USA
THIS WORKSHOP IS SUPPORTED BY
46
iMig2016.ORG
Together, We’ll Find a Cure
At Kazan Law, we fight for justice and
financial compensation for mesothelioma
victims and their families. But our
commitment doesn’t end there: We also seek
to better understand this fatal illness and,
ultimately, help you find a cure.
That’s why the Kazan McClain Partners’
Foundation has steadfastly invested in
supporting the research behind many of
today’s mesothelioma medical insights and
breakthroughs. To the right are some of our
Foundation’s most recent endeavors.
Over $6,000,000 for Research
The Kazan McClain Partners’ Foundation
helps support mesothelioma research at leading
medical facilities and has supported iMig since
2006 at meetings all over the world. We partner
with esteemed learning institutions to find a
cure for asbestos diseases.
A Few of the Research Studies
Supported by Kazan Law
• Whole exome and targeted deep
sequencing identify genome-wide allelic
loss and frequent SETDB1 mutations in
malignant pleural mesotheliomas
(Hio Chung Kang, et al, University of
California San Francisco)
Oncotarget, Advanced Publications 2016
• miR-1 Induces Growth Arrest and
Apoptosis in Malignant Mesothelioma
(Yue Xu, et al, Stanford University)
Chest 2013
• Radiologic–pathologic correlation of
mesothelioma tumor volume
(Samuel G. Armato III, et al, University of Chicago)
Lung Cancer, Elsevier 2014
$100,000 to Honor iMig Attendees
At iMig 2014 in Cape Town we offered $100,000 in micro grants to support research conducted
by iMig attendees. This year in Birmingham, we again invite iMig attendees to apply for grants
from $1,000 up to $25,000.*
iMig Young Investigator Awards
Since 2006, Kazan Law has been a proud and major financial supporter of iMig. We proposed the
Young Investigator Awards program, which we helped to fund in 2008 and have funded it ever
since, and have committed to continue funding in the years ahead.
*Please send a brief email to [email protected] explaining how much money you need, what you will spend it on, and what
publishable goals you hope to accomplish.
For more information,
visit www.kazanlaw.com/iMig-2016 to learn more about what we do.
INDUSTRY-SUPPORTED SYMPOSIA
Tuesday, May 3
Mesothelioma: Moving Forward
08:00 – 08:45
“Surgical Innovations in
Thoracic Surgery”
Hedy Kindler, University of Chicago
Medical Center, USA
13:50
ISS02.03: The Promise of ImmunoOncology in the Treatment of
Michele Maio, Istituto Toscano Tumori,
Italy
Hall 9
Chair: Raja Flores, Mount Sinai Health System,
USA
08:00
ISS01.01: The Use of Permacol™
Surgical Implant in EPD Surgery
David Waller, Glenfield Hospital, United
Kingdom
08:15
ISS01.02: The Use of Biological Mesh
in Chest Wall Reconstruction
Marco Scarci, Papworth Hospital NHS
08:30
ISS01.03: The Use of Buttressing in
Emphysematic Lung States
Walter Weder, University Hospital Zürich,
Switzerland
SUPPORTED BY
Wednesday, May 4 08:00 – 08:45
“Future Directions: Enhancing
Therapies through Immuno-Oncology
Combinations”
Hall 6
Moderator: Daniel H. Sterman, NYU Langone Medical Center, USA
SUPPORTED BY
8:00
ISS03.01: Introductions
8:05
ISS03.02: Rational Combinations
in Immuno-Oncology (IO)
Evan W. Alley, Penn Presbyterian Medical
Center, USA
8:25
ISS03.03: Immunotherapy
Combinations in Mesothelioma
Chair: Michele Maio, Istituto Toscano Tumori,
Italy
Dean Fennell, University of Leicester &
Leicester University Hospitals
13:20
ISS02.01: The Role of Surgery
in the Treatment of Malignant
Mesothelioma
RSVP at https://imig2016symposium-immunooncology-combinations.eventbrite.com
Hospital, USA
13:35
ISS02.02: Systemic Therapy for
Tuesday, May 3
13:15 – 14:15
“State of the Art Treatment of
Malignant Mesothelioma”
Hall 9
iMig2016.ORG
SUPPORTED BY
49
EXHIBITION INFORMATION
Exhibition Location and Hours
Exhibition Highlights
The iMig 2016 Exhibition is located in
Hall 3 of the ICC.
Welcome Networking Reception
Sunday, May 1
Exhibition Opening Hours
Sunday, May 1
18:30 – 21:30
(Opening Networking Reception)
Monday, May 2
10:30 – 19:30
Tuesday, May 3
10:30 – 19:30
Wednesday, May 4
10:30 – 12:00
18:30 – 21:30
Included with full Conference Registration,
not included in Single-Day Registration
Additional tickets for family and friends
can be purchased for £40 at Registration
The iMig 2016 Exhibition will open with the
Welcome Networking Reception, allowing
you the opportunity to mix and mingle with
exhibitors, colleagues and friends.
SUPPORTED BY
d
w ed V
.u ic is
ni at it
te ed o
le w ur
ga e
ls bs
er it
vi e:
ce
s.
or
g
w
w
Free, expert legal support from
Unite Legal Services
Unite members and their families get free legal support for
mesothelioma claims, and will always keep 100% compensation.
Contact Unite Legal
Services first and get:
Free representation for
any asbestos-related
disease claim, including
mesothelioma
Expert legal advice from
highly experienced
asbestos disease solicitors
100% compensation
within the union scheme
“
Unite Legal Servic was fantastic.
 sat down with me and
went through my emplment hiﬆory.
I worked out actly en I had been in
contact with asbtos and th pursued
a compensation claim on my behalf.
Charlie, Unite member
For expert mesothelioma legal support
call Unite Legal Services on:
0800 709 007 www.unitelegalservices.org
@UniteLegal
”
EXHIBITOR LISTING
ALPHABETICAL
Company
Asbestos Disease Awareness
Organization
Asbestos Victims Support
Groups Forum Bayer HealthCare
Pharmaceuticals, Inc.
Boyes Turner LLP
British Thoracic Oncology
Group (BTOG)
CareFusion
Fieldfisher - Mesothelioma
Claims Specialists
Fujirebio
Hope Foundation for
Cancer Research Hugh James
IBAS, International Ban
Asbestos Secretariat
International Thoracic
Oncology Nursing Forum
Irwin Mitchell
June Hancock Mesothelioma
Research Fund
Leigh Day Lawyers
Lilly Oncology
Macmillan Cancer Support
Medtronic
Mesothelioma UK Charitable Trust
MesobanK
Mesothelioma Applied
Research Foundation
MSD Oncology Novum Law
Rocket Medical
Slater & Gordon
Tissuemed Ltd.
54
NUMERICAL
Booth #
TT6
TT8
15
9
TT2
10
16
5
TT9
13
14
TT3
18
TT5
8
1
TT7
11
TT1
4
TT4
12
19
7
17
6
Booth #
1
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
TT1
TT2
TT3
TT4
TT5 TT6
TT7
TT8
TT9
Company
Lilly Oncology
MesobanK
Fujirebio
Tissuemed Ltd.
Rocket Medical
Leigh Day Lawyers
Boyes Turner LLP
CareFusion
Medtronic
MSD Oncology
Hugh James
IBAS, International Ban
Asbestos Secretariat
Bayer HealthCare
Pharmaceuticals, Inc.
Fieldfisher - Mesothelioma
Claims Specialists
Slater & Gordon
Irwin Mitchell
Novum Law
British Thoracic Oncology
Group (BTOG)
International Thoracic
Oncology Nursing Forum
Mesothelioma Applied
Research Foundation
June Hancock Mesothelioma
Research Fund
Asbestos Disease Awareness
Organization
Asbestos Victims Support
Groups Forum
Hope Foundation for
Cancer Research
iMig2016.ORG
EXHIBITION FLOOR PLAN
iMig2016.ORG
55
EXHIBITOR BIOGRAPHIES
Asbestos Disease Awareness Organization
Table # TT6
Asbestos Disease Awareness Organization (ADAO), an independent nonprofit,
was founded by the Reinstein and Larkin families in 2004. ADAO remains
dedicated to raising public awareness about the dangers of asbestos exposure,
advocating for an asbestos ban, and protecting asbestos victims’ civil rights
through our education, advocacy, and community initiatives. (www.adao.us)
Asbestos Victims Support Groups Forum
Table # TT8
The Asbestos Victims Support Groups Forum UK is the umbrella organisation
for asbestos victims support groups in the UK. We work collectively to provide
one voice for asbestos victims nationwide. We provide advice and support for
people diagnosed with asbestos diseases and their families and campaign for
justice for all asbestos victims. (www.asbestosforum.org.uk)
Bayer HealthCare Pharmaceuticals, Inc.
Booth # 15
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of
innovative treatments. Bayer’s oncology franchise now includes three oncology products
and several other compounds in various stages of clinical development. (www.bayer.com)
Boyes Turner
Booth # 9
Boyes Turner’s asbestos team, dedicated to campaigning for the rights of asbestos victims,
working to secure justice for those diagnosed with asbestos conditions and committed to
assisting asbestos disease sufferers with the consequences of their illness, is delighted
and proud to support iMig 2016. (www.boyesturner.com)
British Thoracic Oncology Group (BTOG)
Table # TT2
The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for
professionals involved with thoracic malignancies. BTOG aims to improve the care of
patients with thoracic malignancies through multidisciplinary education, developing and
advising on guidelines for patient care and facilitating and nurturing clinical trial ideas
into full protocols. (www.btog.org)
CareFusion
Booth # 10
The PleurX® catheter system is the easy-to-use and effective choice for
managing recurrent malignant pleural effusions and malignant ascites.
PleurX® has been used to treat more than 300,000 patients since 1997
and could help your patients take control by enabling them to manage
symptoms associated with fluid build-up at home. (www.carefusion.com)
56
iMig2016.ORG
Fieldfisher - Mesothelioma Claims Specialists
Booth # 16
Fieldfisher is one of the UK’s foremost mesothelioma claims practice. We are
renowned for our success and commitment in asbestos and mesothelioma
claims. We visit clients at home and act on a ‘no win, no fee’ basis. Legal 500,
describe us as being ‘in a league of their own nationally’ and ‘head and
shoulders above the rest in terms of skills, experience and quality’. (www.
fieldfisher.com)
Fujirebio
Booth # 5
Fujirebio is a leading international healthcare company and world-wide leader
in Oncology who develops and markets high quality and robust IVD solutions.
Utilising the Lumipulse G series automated CLEIA analysers, the product
portfolio includes both routine and unique immunoassays, including Soluble
Mesothelin Related Peptide (SMRP) and KL-6. (www.fujirebio-europe.com)
Hope Foundation for Cancer Research
Table # TT9
Hope Against Cancer is Leicestershire and Rutland’s local cancer research
charity. We were established in 2003 to bring cutting-edge research to our area
and make clinical trials available to local people. Since 2003 we have raised
almost £4m and funded 40 research projects tackling many different forms of cancer. (www.hfcr.org)
Hugh James
Booth # 13
Hugh James’s industrial disease team represents individuals and their
families who are suffering from respiratory illnesses acquired through
employment. The firm’s expert solicitors make the claims process simple
and straightforward and offer free, no obligation, initial advice as well as
arranging home visits across England and Wales. (www.hughjames.com)
IASLC
Booth # TT10
The International Association for the Study of Lung Cancer (IASLC) is the
only global organization dedicated to the study of lung cancer. Founded in
1974, the association’s membership includes more than 5,000 lung cancer
specialists in over 100 countries. IASLC members work to enhance the
understanding of lung cancer among scientists, members of the medical
community and the public. (www.iaslc.org)
IBAS, International Ban Asbestos Secretariat
Booth # 14
The International Ban Asbestos Secretariat (IBAS), established in 2000, provides a
conduit for the exchange of information between groups and individuals working to
achieve a global asbestos ban and alleviate the damage caused by widespread asbestos
use. IBAS channels the views of a network of victims’ groups, medical and legal
professionals and concerned individuals to raise awareness of asbestos hazards and
provide informed comment on current developments. (www.ibasecretariat.org)
iMig2016.ORG
57
International Thoracic Oncology Nursing Forum
Table # TT3
The ITONF is an organisation for Nurses who are directly caring for people with lung
cancer or mesothelioma and who have a common focus of improving patient care,
health care delivery and outcomes for patients. This network provides an opportunity
for debate, education and knowledge transfer. Membership is free.
(www.itonf.com)
Irwin Mitchell
Booth # 18
Irwin Mitchell LLP has over 30 years’ experience in successfully recovering
compensation for clients whose lives are affected by mesothelioma and other
asbestos-related illnesses. Our specialist solicitors, based in 11 Regional
Offices, have helped and supported several thousand clients after exposure
to asbestos through their work, domestic or environmental circumstances.
(www.irwinmitchell.com)
June Hancock Mesothelioma Research Fund
Table # TT5
The June Hancock Mesothelioma Research Fund (JHMRF) is an independent UK-based charity dedicated to funding high quality research and
providing information and support to patients and their families. The charity
was founded in 1997 and has raised over £1.5m. JHMRF has funded several
major research projects, PhD and travel fellowships.
(www.junehancockfund.org)
Leigh Day Lawyers
Booth # 8
Leigh Day is a law firm with a formidable reputation in asbestos litigation as
a consequence of representing victims for over 25 years in the UK and
abroad. Our cases set precedents. We have good relationships with medical
practitioners. We give lectures on asbestos disease. One of our lawyers has
raised over £60,000 to help fund research into a cure for mesothelioma.
(www.asbestos.leighday.co.uk)
Lilly Oncology
Booth # 1
For more than fifty years, Lilly has been dedicated to delivering
life-changing medicines and support to people living with cancer and
those who care for them. Lilly is determined to build on this heritage
and continue making life better for all those affected by cancer around
the world. (www.lilly.co.uk)
Table # TT7
The Health and Social Care team from Macmillan Cancer Support
covers a wide range of services. They influence policy and opinion
leaders, support service improvement and work with partner organisations to implement new service models. The team has four Programmes
supporting the cancer care pathway; prevention and diagnosis;
treatment and recovery; workforce (including carers); and end of life
care. (www.macmillan.org.uk)
58
iMig2016.ORG
Medtronic
Booth # 11
As a global leader in medical technology, services and solutions,
Medtronic improves the lives and health of millions of people each year.
We use our deep clinical, therapeutic, and economic expertise to address
the complex challenges faced by healthcare systems today. Let’s take
healthcare Further, Together. (Medtronic.com)
Table # TT1
Mesothelioma UK Charitable Trust is a national charity, hosted by
University Hospitals of Leicester. The charity provides support to all
those affected by mesothelioma, providing impartial, up-to-date
information and advice, access to specialist advice through the free
phone helpline, the website and printed patient information.
(www.mesothelioma.uk.com)
MesobanK
Booth # 4
MesobanK is the UK’s largest unique collection of high-quality tissue, cell,
blood samples and data from mesothelioma patients. Novel cell lines and
a TMA of >800 patients also available. MesobanK is dedicated to the study
of mesothelioma by providing samples for research. (www.mesobank.com)
Mesothelioma Applied Research Foundation
Table # TT4
The Mesothelioma Applied Research Foundation is the only 501(c)(3)
nonprofit organization dedicated to eradicating mesothelioma and
the suffering caused by this cancer. The organization: • Funds
mesothelioma research and has awarded over $9.3 million to date; •
Provides patient support services and education; • Advocates
Congress for increased federal funding for mesothelioma research.
(www.curemeso.org)
MSD Oncology
Booth # 12
Our goal is to translate breakthrough science into innovative oncology
medicines to help people with cancer worldwide. At MSD Oncology, helping
people fight cancer is our passion and supporting accessibility to our cancer
medicines is our commitment. Our focus is on pursuing research in immuno-oncology and we are accelerating every step in the journey – from lab to
clinic – to potentially bring new hope to people with cancer. (www.msd-uk.com)
Novum Law
Booth # 19
At Novum Law, we are experts in dealing with mesothelioma and asbestos-related diseases. Our specialist asbestos team have substantial
experience in dealing with these highly complex cases and have recovered
millions of pounds of compensation for hundreds of clients. We cannot
change the diagnosis but we can help to get financial compensation that can
bring some peace of mind for the future. (www.novumlaw.com)
iMig2016.ORG
59
Rocket Medical
Booth # 7
Rocket Medical UK manufacturers of Indwelling Pleural and Peritoneal
Catheters and their associated consumables. We have over 8 years
experience of caring for patients with Pleural Effusions and abdominal
ascites associated with Mesothelioma. We will have all the products for
you to handle on our stand and will be available to demonstrate the
products and answer any queries. (www.rocketmedical.com)
Slater & Gordon
Booth # 17
Slater and Gordon have many years’ experience representing people exposed to
asbestos who develop mesothelioma. With offices throughout Australia and the
UK, our specialist lawyers have been involved in some of the most important and
ground-breaking asbestos cases. (www.slatergordon.co.uk)
Tissuemed Ltd.
Booth # 6
Tissuemed is a UK company that develops, manufactures and supplies
TissuePatch™, a synthetic, self-adhesive, absorbable surgical reinforcement
and sealant film. TissuePatch™ requires zero preparation, is easy to apply,
and is a functionally and economically effective method of managing
persistent air leaks in both open and VATS procedures. (www.tissuemed.com)
Understanding that
mesothelioma also affects
those closest to you.
With a dedicated team of solicitors we make
every effort to tailor the support and advice
you and your family need, because we know the
impact of your condition is unique and affects
each person differently. Irwin Mitchell, standing
by you.
0370 1500 100
www.irwinmitchell.com
@irwinmitchell
For a list of our offices visit our website . Irwin Mitchell LLP is a limited liability partnership registered in England & Wales, with number OC343897, and is authorised and regulated by
the Solicitors
Regulation
Authority. All Scottish
cases will be handled
a separate
Scottish legal practice,
Irwin Mitchell Scotland
LLP, which is regulated
Law Society of Scotland.
13TH
INTERNATIONAL
CONFERENCE
OFbyTHE
I NTERNATIONAL
MESOTHELIOMA
INTEREST
GROUPby theiMig2016.ORG
60
Like You, We Provide Personalized Care
As a clinician or research scientist, you look beyond the science to provide compassionate and
personalized care for mesothelioma patients.
At Kazan Law, we too provide a full range of services for those suffering from mesothelioma. For 42
years we have provided patients with access to resources and information and a voice in court, along
with a commitment to supporting the research that will, someday, lead us to a cure.
Our patient pathway offers multiple levels of care, including:
• Research funding— The Kazan McClain Partners’ Foundation has proudly contributed more
than $6 million to mesothelioma awareness and research, and will continue to do so until there
is a cure.
• Ban Asbestos— The firm and its Foundation has been a major financial supporter of the
International Ban Asbestos movement for over 20 years.
• Top verdicts and settlements— Won on behalf of mesothelioma patients exposed to asbestos
by unfeeling corporations. While money cannot replace a patient’s life, it can prevent
additional, undue suffering of family members by paying the bills.
• Mesothelioma Circle—A website devoted to mesothelioma patients and their loved ones, filled
with resources and information on medical treatments, clinical trials, legal rights, and more.
Let’s work together to ensure that mesothelioma patients get the personalized health care
and financial support they need during an emotional and painful time in their lives.
Visit www.kazanlaw.com/iMig-2016 to learn more about our services.

onsite programme

Transcription

Similar documents

Mesothelioma Takes Our Heroes

First-in-Human Phase I administration of YS110, a humanized

Newsletter - Mesothelioma UK

Asbestos - Fieldfisher

Read Publication - Institute For Respiratory Health

Summer 2012 - USS Ozbourn (DD-846)

Breakout A: Corporate Client Panel

Mesothelioma - Cancer Council SA

Asbestos in Schools Bkl

PleurX™ catheter system